US20030195404A1 - Method and apparatus for real-time control of physiological parameters - Google Patents

Method and apparatus for real-time control of physiological parameters Download PDF

Info

Publication number
US20030195404A1
US20030195404A1 US10417438 US41743803A US2003195404A1 US 20030195404 A1 US20030195404 A1 US 20030195404A1 US 10417438 US10417438 US 10417438 US 41743803 A US41743803 A US 41743803A US 2003195404 A1 US2003195404 A1 US 2003195404A1
Authority
US
Grant status
Application
Patent type
Prior art keywords
time
glucose
estimator
embodiment
optimal
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
US10417438
Inventor
Edward Knobbe
Wah Lim
Bruce Buckingham
Original Assignee
Knobbe Edward J.
Lim Wah L.
Buckingham Bruce A.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date

Links

Images

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61BDIAGNOSIS; SURGERY; IDENTIFICATION
    • A61B5/00Detecting, measuring or recording for diagnostic purposes; Identification of persons
    • A61B5/0002Remote monitoring of patients using telemetry, e.g. transmission of vital signals via a communication network
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61BDIAGNOSIS; SURGERY; IDENTIFICATION
    • A61B5/00Detecting, measuring or recording for diagnostic purposes; Identification of persons
    • A61B5/145Measuring characteristics of blood in vivo, e.g. gas concentration, pH value; Measuring characteristics of body fluids or tissues, e.g. interstitial fluid, cerebral tissue
    • A61B5/14532Measuring characteristics of blood in vivo, e.g. gas concentration, pH value; Measuring characteristics of body fluids or tissues, e.g. interstitial fluid, cerebral tissue for measuring glucose, e.g. by tissue impedance measurement
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61BDIAGNOSIS; SURGERY; IDENTIFICATION
    • A61B5/00Detecting, measuring or recording for diagnostic purposes; Identification of persons
    • A61B5/72Signal processing specially adapted for physiological signals or for diagnostic purposes
    • A61B5/7235Details of waveform analysis
    • A61B5/725Details of waveform analysis using specific filters therefor, e.g. Kalman or adaptive filters
    • GPHYSICS
    • G06COMPUTING; CALCULATING; COUNTING
    • G06FELECTRIC DIGITAL DATA PROCESSING
    • G06F19/00Digital computing or data processing equipment or methods, specially adapted for specific applications
    • G06F19/30Medical informatics, i.e. computer-based analysis or dissemination of patient or disease data
    • G06F19/34Computer-assisted medical diagnosis or treatment, e.g. computerised prescription or delivery of medication or diets, computerised local control of medical devices, medical expert systems or telemedicine
    • G06F19/3456Computer-assisted prescription or delivery of medication, e.g. prescription filling or compliance checking
    • GPHYSICS
    • G16INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
    • G16HHEALTHCARE INFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR THE HANDLING OR PROCESSING OF MEDICAL OR HEALTHCARE DATA
    • G16H10/00ICT specially adapted for the handling or processing of patient-related medical or healthcare data
    • G16H10/40ICT specially adapted for the handling or processing of patient-related medical or healthcare data for data related to laboratory analysis, e.g. patient specimen analysis
    • GPHYSICS
    • G16INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
    • G16HHEALTHCARE INFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR THE HANDLING OR PROCESSING OF MEDICAL OR HEALTHCARE DATA
    • G16H50/00ICT specially adapted for medical diagnosis, medical simulation or medical data mining; ICT specially adapted for detecting, monitoring or modelling epidemics or pandemics
    • G16H50/50ICT specially adapted for medical diagnosis, medical simulation or medical data mining; ICT specially adapted for detecting, monitoring or modelling epidemics or pandemics for simulation or modelling of medical disorders
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61BDIAGNOSIS; SURGERY; IDENTIFICATION
    • A61B2560/00Constructional details of operational features of apparatus; Accessories for medical measuring apparatus
    • A61B2560/02Operational features
    • A61B2560/0242Operational features adapted to measure environmental factors, e.g. temperature, pollution
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61MDEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
    • A61M2230/00Measuring parameters of the user
    • A61M2230/20Blood composition characteristics
    • A61M2230/201Glucose concentration
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61MDEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
    • A61M5/00Devices for bringing media into the body in a subcutaneous, intra-vascular or intramuscular way; Accessories therefor, e.g. filling or cleaning devices, arm-rests
    • A61M5/14Infusion devices, e.g. infusing by gravity; Blood infusion; Accessories therefor
    • A61M5/142Pressure infusion, e.g. using pumps
    • GPHYSICS
    • G06COMPUTING; CALCULATING; COUNTING
    • G06FELECTRIC DIGITAL DATA PROCESSING
    • G06F19/00Digital computing or data processing equipment or methods, specially adapted for specific applications
    • G06F19/30Medical informatics, i.e. computer-based analysis or dissemination of patient or disease data
    • G06F19/34Computer-assisted medical diagnosis or treatment, e.g. computerised prescription or delivery of medication or diets, computerised local control of medical devices, medical expert systems or telemedicine
    • G06F19/3481Computer-assisted prescription or delivery of treatment by physical action, e.g. surgery or physical exercise
    • YGENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02ATECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A90/00Technologies having an indirect contribution to adaptation to climate change
    • Y02A90/10Information and communication technologies [ICT] supporting adaptation to climate change.
    • Y02A90/20Information and communication technologies [ICT] supporting adaptation to climate change. specially adapted for the handling or processing of medical or healthcare data, relating to climate change
    • Y02A90/26Information and communication technologies [ICT] supporting adaptation to climate change. specially adapted for the handling or processing of medical or healthcare data, relating to climate change for diagnosis or treatment, for medical simulation or for handling medical devices
    • YGENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10STECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10S128/00Surgery
    • Y10S128/92Computer assisted medical diagnostics
    • Y10S128/923Computer assisted medical diagnostics by comparison of patient data to other data
    • YGENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10STECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10S128/00Surgery
    • Y10S128/92Computer assisted medical diagnostics
    • Y10S128/923Computer assisted medical diagnostics by comparison of patient data to other data
    • Y10S128/924Computer assisted medical diagnostics by comparison of patient data to other data using artificial intelligence

Abstract

A real-time controller operating as an artificial pancreas uses a Kalman control algorithm to control glucose level of a patient in real time. The real-time controller receives an estimate of the patient glucose level and a reference glucose level. The estimate of the patient glucose level can be provided by an optimal estimator implemented using a linearized Kalman filter. The estimated glucose level and the reference glucose level are processed by the Kalman control algorithm to determine a control command in real time. The Kalman control algorithm has a dynamic process forced by the control command a cost function determining a relative level of control. The control command is provided to a dispenser which secretes insulin or glucagon in response to the control command to correct a relatively high glucose level or a relatively low glucose level.

Description

    PRIORITY CLAIM
  • [0001]
    This application is a continuation of U.S. application Ser. No. 09/960,855, filed on Sep. 21, 2001, which claims the benefit of U.S. Provisional Application No. 60/234,632, filed on Sep. 22, 2000, and entitled Real Time Estimation & Control Of Biological Process.
  • COPYRIGHT RIGHTS
  • [0002]
    A portion of the disclosure of this patent document contains material that is subject to copyright protection. The copyright owner has no objection to the facsimile reproduction by anyone of the patent document or of the patent disclosure as it appears in the Patent and Trademark Office patent files or records, but otherwise reserves all copyright rights whatsoever.
  • BACKGROUND OF THE INVENTION
  • [0003]
    1. Field of the Invention
  • [0004]
    This present invention relates generally to a method and apparatus for controlling physiological parameters and more particularly to an optimal controller for controlling glucose levels in a patient.
  • [0005]
    2. Description of the Related Art
  • [0006]
    Different types of sensors (e.g., optical sensors) are available for monitoring of physiological parameters (e.g., glucose concentration). Glucose monitoring is typically performed by people with diabetes mellitus which is a medical condition involving a body's inability to produce the quantity or quality of insulin needed to maintain a normal circulating blood glucose. Frequent monitoring of glucose is generally necessary to provide effective treatment and to prevent long term complications of diabetes (e.g., blindness, kidney failure, heart failure, etc.). New methods of monitoring glucose are fast, painless and convenient alternatives to the typical capillary blood glucose (CBG) measurements which involve finger pricks that are painful, inconvenient and difficult to perform for long term.
  • [0007]
    Optical measurement of glucose is performed by focusing a beam of light onto the body. Optical sensors determine glucose concentration by analyzing optical signal changes in wavelength, polarization or intensity of light. However, many factors other than glucose concentration also contribute to the optical signal changes. For example, sensor characteristics (e.g., aging), environmental variations (e.g., changes in temperature, humidity, skin hydration, pH, etc.), and physiological variations (e.g., changes in tissue fluid due to activity, diet, medication or hormone fluctuations) affect sensor measurements.
  • [0008]
    Various methods are used to improve the accuracy of the sensor measurements. One method (e.g., multivariate spectral analysis) utilizes calibration models developed by initially measuring known glucose concentrations to correct subsequent sensor measurements. The calibration models become inaccurate over time due to dynamic changes in physiological processes. Another method (e.g., adaptive noise canceling) utilizes signal processing to cancel portions of the sensor measurements unrelated to glucose concentration. For example, two substantially simultaneous sensor measurements at different wavelengths make up a composite signal which can be processed to cancel its unknown and erratic portions. However, many sensors do not provide substantially simultaneous measurements at two different wavelengths.
  • SUMMARY OF THE INVENTION
  • [0009]
    The present invention solves these and other problems by providing a method and apparatus for making optimal estimates of a physiological parameter (e.g., glucose level), assessing reliability of the optimal estimates, and/or providing optimal control of the physiological parameter in real time using one or more sensor measurements at each measurement time epoch (or interval). The sensor measurements can be time-based (e.g., every five minutes) to provide continuous monitoring and/or regulation of the physiological parameter. The sensor measurements are a function of the physiological parameter within specified uncertainties.
  • [0010]
    An optimal estimator provides an accurate estimate of glucose level in real time using a sensor with at least one output. In one embodiment, the optimal estimator is integrated with the sensor and an output display to be a compact glucose monitoring device which can be worn by a patient for continuous monitoring and real-time display of glucose level. In an alternate embodiment, the optimal estimator is a separate unit which can interface with different types of sensors and provide one or more outputs for display, further processing by another device, or storage on a memory device.
  • [0011]
    In one embodiment, the optimal estimator employs a priori deterministic dynamic models developed with stochastic variables and uncertain parameters to make estimates of glucose level. For example, glucose level is defined as one of the stochastic (or random) variables. Dynamic mathematical models define process propagation (i.e., how physiological and sensor parameters change in time) and measurement relationship (i.e., how physiological and sensor parameters relate to environmental conditions). Environmental conditions (e.g., temperature, humidity, pH, patient activity, etc.) can be provided to the optimal estimator intermittently or periodically via environment sensors and/or data entries by a patient or a doctor.
  • [0012]
    The optimal estimator uses dynamic models to propagate estimates of respective stochastic variables, error variances, and error covariances forward in time. At each measurement time epoch, the optimal estimator generates real-time estimates of the stochastic variables using one or more sensor outputs and any ancillary input related to environmental conditions. In one embodiment, the optimal estimator employs a linearized Kalman filter to perform optimal estimation of the stochastic variables (e.g., glucose level). In particular, an extended Kalman filter is used to accommodate nonlinear stochastic models.
  • [0013]
    Before making real-time estimates, the optimal estimator is initialized by providing initial values for the stochastic variables, error variances, and error covariances. For example, a CBG measurement or another direct glucose measurement is performed at initialization to provide a starting value for the stochastic variable corresponding to glucose level.
  • [0014]
    In one embodiment, the optimal estimator provides one or more outputs to a patient health monitor which is capable of optimized real-time decisions and displays. The patient health monitor evaluates system performance by assessing the performance of the sensor and/or optimal estimator in real time. For example, the patient health monitor applies statistical testing to determine the reliability of the real-time estimates of the stochastic variables by the optimal estimator. The statistical testing is performed in real time on residual errors of the optimal estimator to establish performance measures.
  • [0015]
    In one embodiment, the patient health monitor acts as an input/output interface between the patient or medical staff (e.g., a doctor, nurse, or other healthcare provider) and the optimal estimator. For example, environmental conditions can be provided to the patient health monitor for forwarding to the optimal estimator. Optimal estimator outputs can be provided to the patient health monitor for display or forwarding to an external device (e.g., a computer or a data storage device).
  • [0016]
    In one embodiment, the optimal estimator provides one or more outputs to an optimal controller which can regulate in real time the physiological parameter being monitored. For example, an optimal controller responds to real-time optimal estimator outputs and provides an output to operate an actuator. In the case of glucose control, the actuator can be a dispenser or a pump which secretes insulin to correct a relatively high glucose level and glucagon to correct a relatively low glucose level. The optimal controller takes advantage of a priori information regarding the statistical characteristics of the actuator and is able to control the output of the actuator to be within specified uncertainties.
  • [0017]
    In one embodiment, the optimal estimator and the optimal controller form an optimal closed-loop system. For example, a glucose sensor, an optimal estimator, an optimal controller, and an insulin/glucagon dispenser work together as an artificial pancreas to continuously regulate glucose level. The glucose sensor can be internal or external to a patient's body. The optimal controller provides a control feedback to the optimal estimator to account for delivery of the insulin/glucagon.
  • [0018]
    The optimal closed-loop system is effective in a variety of biomedical applications. For example, cardiovascular functions can be continuously regulated by using sensors to detect blood pressure, blood oxygen level, physical activity and the like, an optimal estimator to process the sensor measurements and make real-time estimates of heart function parameters, and an optimal controller to control operations of an artificial device (e.g., a pacemaker) in real time based on the real-time estimates from the optimal estimator to achieve a set of desired heart function parameter values. Other artificial devices (e.g., artificial limbs, bionic ears, and bionic eyes) can be part of similar optimal closed-loop systems with sensors detecting nerve signals or other appropriate signals.
  • [0019]
    The optimal closed-loop system is also effective in optimal treatment of chronic illnesses (e.g., HIV). Some medications for treatment of chronic illnesses are relatively toxic to the body. Over delivery of medication generally has adverse effects on the patient. The optimal closed-loop system is capable of providing effective and safe treatment for the patient. For example, an optimal estimator provides real-time estimates of key physiological parameters using one or more sensors, and an optimal controller controls a slow infusion of medication in real time based on the real-time estimates from the optimal estimator to obtain desirable values for the key physiological parameters.
  • [0020]
    In one embodiment, the optimal estimator, patient health monitor, and optimal controller are software algorithms which can be implemented using respective microprocessors. New information regarding process propagation or measurement relationship can be easily incorporated by modifying, reconfiguring, and/or adding to the software algorithms. The optimal estimator, patient health monitor, and optimal controller can be implemented as one joint algorithm or separate respective algorithms which function together to provide an optimal closed-loop system.
  • BRIEF DESCRIPTION OF THE DRAWINGS
  • [0021]
    [0021]FIG. 1A is a block diagram of one embodiment of an estimator.
  • [0022]
    [0022]FIG. 1B is a block diagram of another embodiment of a glucose-monitoring device.
  • [0023]
    [0023]FIG. 2 illustrates one embodiment of modeling physiological processes in a linearized Kalman filter application.
  • [0024]
    [0024]FIG. 3A describes one embodiment of an estimation function which depicts a linearized Kalman filter formulation.
  • [0025]
    [0025]FIG. 3B illustrates an initialization in one embodiment of an optimal estimator.
  • [0026]
    [0026]FIG. 3C illustrates a time-update cycle in accordance with one embodiment of an optimal estimator.
  • [0027]
    [0027]FIG. 3D illustrates a measurement-update cycle in accordance with one embodiment of an optimal estimator.
  • [0028]
    [0028]FIGS. 4A and 4B illustrate a first set of time history plots of optimal glucose estimates and CBG measurements with respect to time.
  • [0029]
    [0029]FIGS. 5A and 5B illustrate a second set of time history plots of optimal glucose estimates and CBG measurements with respect to time.
  • [0030]
    [0030]FIG. 6A is a block diagram of one embodiment of a patient health monitor.
  • [0031]
    [0031]FIG. 6B illustrates one embodiment of a residual test data process in the patient health monitor.
  • [0032]
    [0032]FIG. 6C illustrates one embodiment of a statistical test process in the patient health monitor.
  • [0033]
    [0033]FIG. 6D illustrates one embodiment of an input/output interface in the patient health monitor.
  • [0034]
    [0034]FIGS. 7A and 7B illustrate time history plots of residual test data with respect to measurement time.
  • [0035]
    [0035]FIG. 8 is a functional diagram of one embodiment of an artificial pancreas.
  • [0036]
    [0036]FIG. 9A illustrates one embodiment of an optimal controller for a closed loop system.
  • [0037]
    [0037]FIG. 9B illustrates one embodiment of a control model for a controller in accordance with the present invention.
  • [0038]
    [0038]FIG. 9C illustrates one embodiment of a control algorithm.
  • DETAILED DESCRIPTION OF THE PREFERRED EMBODIMENT
  • [0039]
    The present invention involves application of real-time optimal estimation, optimized real-time decisions and displays (e.g., a patient health monitor), or optimal real-time control to physiological processes. In one embodiment, the real-time optimal estimation, the optimized real-time decisions and displays, and the optimal real-time control are implemented as separate modules which can be combined functionally. In an alternate embodiment, the real-time optimal estimation, the optimized real-time decisions and displays, and the optimal real-time control are implemented as one joint algorithm.
  • [0040]
    In one embodiment, input to an optimal estimator is provided by a physical sensor (or a plurality of sensors) which measures some arbitrary, but known, function (or functions) of variables or parameters to be estimated to within specified uncertainties and whose statistical characteristics are known. In one embodiment, an output of a real-time controller is provided to a physical controllable dispenser, or actuator, whose output is some known function of parameters to be controlled within specified uncertainties and whose statistical characteristics are known. In one embodiment, a decision and display function utilizes statistical testing of estimator residual errors using internally computed, and updated, estimator variances and covariances.
  • [0041]
    In one embodiment, the present invention is implemented as a software algorithm. The present invention uses models (e.g., dynamic process and measurement models). For best performance, the models should reflect the latest and most complete information available. As new and more complete information is developed, performance can be improved through incorporation of this information by simply modifying the software algorithm of the present invention.
  • [0042]
    Embodiments of the present invention will be described hereinafter with reference to the drawings. FIG. 1A is a block diagram of one embodiment of an estimator. The estimator uses a linearized Kalman filter. The linearized Kalman filter accommodates nonlinear process models and/or nonlinear measurement models. In one embodiment, the linearized Kalman filter is a discrete extended Kalman filter which is linearized after each update using best estimates.
  • [0043]
    A general formulation of a continuous-discrete extended Kalman filter is provided in Table 1. In an alternate embodiment, the linearized Kalman filter is linearized about a nominal set for which a general formulation is given in Table 2.
  • [0044]
    The estimator computes an estimator gain based on time updated and measurement updated error variable variances and covariances. In one embodiment, the estimator is implemented using discrete formulations. In an alternate embodiment, the estimator is implemented using continuous formulations. In the actual development of algorithms, one can choose a Covariance formulation or an Information formulation depending on initialization uncertainty considerations. Further, the use of Bierman factorization techniques (UDU{circumflex over ( )}T) in the implementation leads to numerically stable algorithms which are excellent for operation over very long time periods.
  • [0045]
    In one embodiment, the estimator of FIG. 1A is applied to the problem of monitoring patient glucose levels. Any type of physical sensor which measures some function of glucose can be used. In one embodiment, one or more capillary blood glucose (CBG) measurements are obtained on initialization of the estimator and when estimated glucose deviations exceed computed variance levels.
  • [0046]
    In another embodiment, additional capillary glucose values are obtained on a periodic basis to assess sensor function. As an example, CBG measurements may be obtained once or twice a day pre and one hour post prandial or when the estimator determines that the glucose values are out of range of predetermined limits.
  • [0047]
    In one embodiment, the estimator is contained in a small portable package. The estimator can be operated by a patient. Alternatively, the estimator can be operated by medical staff in a hospital or clinic. The estimator (e.g., Kalman estimator) uses a Kalman filter to provided real-time estimates of patient glucose levels based upon glucose sensor measurements. The Kalman estimator can also use additional information to more closely predict time propagation of glucose levels, such as exercise, food intake, insulin administration, or other factors which influence glucose levels or the function of the sensor (e.g., local pH, temperature or oxygen tension near the physical sensor).
  • [0048]
    [0048]FIG. 1B is a block diagram of one embodiment of a glucose-monitoring device 100. The glucose-monitoring device 100 includes a glucose sensor 108, an ancillary sensor 110, a glucose estimator 114, and a patient health monitor 114. The glucose-monitoring device 100 is used to provide real-time glucose estimates of a patient 102. In one embodiment, the glucose-monitoring device 100 is an integrated unit which is portable by the patient 102 to provide continuous glucose monitoring and real-time displays.
  • [0049]
    The glucose sensor 108 (e.g., a probe, patch, infrared, or laser sensor) is coupled to the patient 102 and outputs a measurement ƒ(g) which is a function of the glucose level of the patient 102. The glucose sensor 108 makes measurements within specified uncertainties and has known statistical characteristics. The glucose sensor 108 provides the measurement ƒ(g) to the glucose estimator 112. In one embodiment, the glucose sensor 108 makes measurements periodically. In an alternate embodiment, the glucose sensor 108 makes measurements intermittently or upon command.
  • [0050]
    The ancillary sensor 110 is coupled to the patient 102, the glucose sensor 108, and/or surroundings of the patient 102 and/or glucose sensor 108 to provide information regarding environmental and/or glucose sensor conditions (e.g., temperature, humidity, local pH, etc.) which affect the measurement. One or more outputs of the ancillary sensor 110 are provided to the glucose estimator 112. In one embodiment, the ancillary sensor 110 provides outputs to the patient health monitor 114 which can process the information for display or for forwarding to the glucose estimator 112. In an alternate embodiment, the ancillary sensor 110 is not a part of the glucose-monitoring device 100.
  • [0051]
    The patient 102 and/or a medical staff 104 (i.e., a user) can provide information on the environmental and glucose sensor conditions as well as other information affecting the measurement. In one embodiment, the patient 102 and/or medical staff 104 inputs information (e.g., exercise activity, food intake, insulin administration, etc.) using the patient health monitor 114. The patient health monitor 114 acts as an input/output interface or a means for the user to configure the glucose estimator 112. The patient health monitor 114 forwards the information to the glucose estimator 112.
  • [0052]
    In one embodiment, the patient health monitor 114 is a display device. For example, an output of the glucose estimator 112 (e.g., an optimal real-time estimate of glucose) is provided to the patient health monitor 114 which displays the information in a comprehensible format for the patient 102 and/or the medical staff 104. The patient health monitor 114 can also contemporaneously display information provided by the glucose sensor 108, the ancillary sensor 110, the patient 102 and/or the medical staff 104 which affects the measurement used to make the optimal glucose estimate.
  • [0053]
    In another embodiment, the patient health monitor 114 is a status indicator. For example, the glucose estimator 112 provides outputs (e.g., residuals and variances) to the patient health monitor 114 which applies statistical testing to determine the reliability of the glucose sensor 108 and/or the glucose estimator 112. The patient health monitor 114 provides a warning when poor performance is detected.
  • [0054]
    In one embodiment, the glucose estimator 112 is a linearized Kalman filter (e.g., a discrete extended Kalman filter) to account for a nonlinear process model and/or measurement model. The glucose estimator (or Kalman estimator) 112 provides real-time estimates of the glucose level in the patient 102. An initialization measurement 106 (e.g., a CBG measurement) is obtained from the patient 102 and provided to the Kalman estimator 112 to initialize the Kalman estimator 112.
  • [0055]
    [0055]FIG. 2 is a flow chart illustrating one embodiment of a modeling process for physiological processes. In one embodiment, physiological processes are described by nonlinear stochastic models. In one embodiment, the flow chart of FIG. 2 illustrates one method of developing a dynamic model for an optimal estimator. The method includes steps for state vector development, nominal dynamic/measurement model development, linearized model development, and uncertainty modeling and nominal model verification.
  • [0056]
    [0056]FIG. 2 illustrates modeling of physiological processes in a linearized Kalman filter application. As an example in glucose estimation, in a first block of FIG. 2, glucose is an estimation variable. The time rate of change of glucose might become another estimation variable. An uncertain parameter might be the glucose sensor scale factor, and additionally, the rate of change of scale factor over time could be another.
  • [0057]
    In one embodiment of a second block of FIG. 2, the way in which variables and parameters nominally propagate over time may change with conditions. In the example of glucose estimation, inputs can be used to identify patient related activities: eating; exercising; sleeping; insulin injection; etc. With these identified patient related activities, additional state variables can be identified and modeled. For example, if patient eating can be related to a change in glucose level over some specified time interval, dynamics can be implemented within the estimator model which will propagate (or extrapolate) a rise in the glucose level over that time interval. This rise may be modeled by appropriate functions whose variables contain uncertainties, which may be added as elements of the state vector. In an analogous way, decreases in glucose levels (e.g., due to insulin injections) can be modeled. These models may be general in nature, or they may be patient specific. Consequently, patient related activities that have a significant impact on glucose levels, or the rate of change of glucose levels, can be accounted for within the dynamic process model.
  • [0058]
    Insofar as sensor modeling is concerned, experience shows that, for example, infrared sensor measurement bias errors vary with, among other things, temperature. If this variation with temperature can be modeled, and included in the process model, then a temperature measurement will improve estimator performance. A particular physical glucose sensor may have a scale factor which has a characteristic decay in sensitivity over time as discussed in further detail below. There may be other variables that can be measured which will affect the physical function of a sensor such as local pH, oxygen tension, etc.
  • [0059]
    In one embodiment, the nominal modeling is comprised of three types: 1) predictable characteristics of a physical sensor function over time (e.g., a fixed rate in decline of sensor output), 2) other measurable physical variables which may affect sensor function (e.g., local temperature, pH, etc.), and 3) predictable changes in the model which occur with patient related activities (e.g., exercise, eating or insulin administration). Changes to the dynamic process model may add variables and/or uncertain parameters to the state vector and changes to measurement models. As a result, the activities indicated in blocks 1 and 2 of FIG. 2 constitute an iterative process.
  • [0060]
    In one embodiment of block 3 of FIG. 2, the relationship between variables, parameters, and measurements determines which parts of the processes and measurements are nonlinear and are linearized. Further, the relationship between variables, parameters, and measurements determines if the variables and parameters are observable and can be estimated. In certain cases, observability can be enhanced through introduction of additional modeling information. For the glucose example, the ability to estimate sensor scale factor and/or detect sensor failure may be improved by modeling glucose propagation changes due to insulin injections or ingestion of sugar. For example, tracking known changes enhances scale factor observability through estimator generated correlations. Further, if it is known that glucose levels vary and the sensor measurement does not change accordingly within prescribed levels of uncertainty, a sensor problem is indicated.
  • [0061]
    In one embodiment of block 4 of FIG. 2, the development of a relatively large database is used to empirically verify and/or modify the nominal nonlinear dynamic process/measurement models and derive uncertainty levels associated with the variables, parameters, and measurements. In one embodiment, the empirical data can be fitted to nonlinear functions using a nonlinear regression package contained in a commercially available software application program such as “Mathematica” from Wolfram Research, Inc. Analytical functions may be added or modified using the test database. The repeatability of the fit over nominal ranges of the patient environment determines the uncertain parameters and the variations establish uncertainty levels. The more accurate the dynamic process and measurement models, the more the uncertainties are reduced, and the greater the estimator performance. As the process evolves, the modeling becomes better defined through iterations between blocks 4 and 2. Certain portions of the models may be developed on an individual basis (e.g., for a specific patient).
  • [0062]
    A database is used to empirically develop and verify models. An embodiment discussed below uses the database to develop two separate dynamic process models. For example, after processing a number of data sets from a physical sensor that was used to monitor the glucose level of various patients, it was observed that the sensor scale factor was equally likely to move up or down over the first fifteen to twenty-five hours. However, the scale factor tended to decay for the remaining life of the sensor after this period of time, usually three or four days. These observations are incorporated in an embodiment of the estimator discussed in further detail below.
  • [0063]
    [0063]FIG. 3A describes an estimation function which depicts a linearized Kalman filter formulation. In one embodiment, the particular form is that of a discrete extended Kalman filter which linearizes after each update using best estimates. In the formulation, a vector whose elements comprise variables and/or parameters (with uncertainties) for making estimates defines the state of a system.
  • [0064]
    There is a distinction between variables (e.g., random variables) and parameters with uncertainty. Variables, such as glucose and rate of change of glucose, are estimated and can be controlled (if control is implemented). Parameters with uncertainty are part of the model structure not known precisely and are estimated and updated (like variables) but not controlled, e.g., a glucose sensor scale factor or insulin dispensing controller scale factor.
  • [0065]
    In one embodiment, real-time variable and parameter estimates are used to re-linearize the model following each update. Inputs to the estimator can consist of any measurement which is related to, or can be correlated with, any element in the state vector. In the case of glucose estimation, other inputs can consist of dynamic process configuration control based on patient related activities or other circumstances. Following initialization, the time update and measurement update cycles form a recursive loop. The time update period is the time interval between the receipt of measurements. This is a function of the sensor and of acceptable latency in the estimates.
  • [0066]
    [0066]FIGS. 3B, 3C and 3D illustrate, respectively, Initialization and the recursive Time Update and Measurement Update cycles according to one embodiment of the present invention. Table 3 defines, in more detail, symbols used in these figures. In one embodiment, dynamic process and measurement modeling is contained in software algorithms with parameter and structure updates in real time.
  • [0067]
    One embodiment of an initialization of the estimation process is described in FIG. 3B. A state vector estimate, Xeo, contains the initial estimates of the process variables and model parameters with uncertainty, while the covariance matrix, Po, contains the initial variances and covariances associated with the Xeo elements.
  • [0068]
    [0068]FIG. 3B shows an example embodiment with a two-element state vector which is based on empirical observations described above. As an example, the point in time when the scale factor begins to decay was chosen as 20 hours, a nominal value over the database. An exponential decay was chosen to model this decay rate and is consistent with the first derivative of scale factor equal to a parameter, alpha, multiplied by the variable scale factor. In this case, alpha is not modeled as an uncertain parameter; a value of 0.012 was chosen as a nominal value, over the database, for the five-minute cycle time of this physical sensor.
  • [0069]
    The initial estimate of glucose is 150 mg/dl (state vector element) with an initial uncertainty variance of 100 mg/dl squared (a covariance matrix element). When processing the data, the glucose element was initialized by setting it substantially equal to the first capillary blood glucose measurement. The nominal initial scale factor value, for the physical sensor, is 0.25 nano-amps/(mg/dl) with a parameter uncertainty (variance) of 0.1 nano-amps/(mg/dl) squared.
  • [0070]
    The initial covariance between the glucose variable and the scale factor parameter is zero. Correlation between glucose and scale factor will develop as the estimator processes the sensor measurements. Each type of sensor will have its own model and characteristics. The measurement uncertainty is 5 nano-amps squared, an element of the R matrix. In one embodiment, this is a scalar measurement and the R matrix contains a single element.
  • [0071]
    A second measurement in this example embodiment is an occasional direct measurement, such as a capillary blood glucose measurement (CBG), with a unity scale factor, and a measurement error uncertainty of 15 mg/dl squared (a single element in a second R matrix). This is probably better modeled as 15% of the measured glucose value. The growth in uncertainty of glucose and scale factor from measurement to measurement is, respectively, 20 mg/dl squared and 0.002 nano-amps squared (elements of the process noise matrix, Q).
  • [0072]
    [0072]FIG. 3C illustrates a time-update process of the recursive process in one embodiment of an optimal estimator. In this figure, a negative superscript indicates a time update while a positive superscript indicates a measurement update. In the brackets, a letter “i” indicates time at the ith interval and (i−1) indicates time at the previous time interval. In an update process, a state vector is first updated since these elements are used to update matrices and to bring the time epoch of the estimated measurement to be consistent with that of the next measurement to be received.
  • [0073]
    In an example embodiment with a two-element state vector, the dynamic process is linear. With no patient inputs, the first derivative of the measured physiologic variable is zero, corresponding to the case when the level (on average) is as likely to either go up or to go down. No additional a priori information is assumed about the time propagation of glucose.
  • [0074]
    In one embodiment of estimating glucose, the solution to the scale factor propagation after the first 20 hours is defined by the exponential shown in the second column. Consequently, for this embodiment, the dynamic process function (f), is linear, is not a function of state vector elements, and, from linear system theory, the transition matrix (A) is the 2 by 2 identity matrix for the first 20 hours and thereafter is defined by the 2 by 2 matrix in the second column.
  • [0075]
    In one embodiment, the measurement function (h) for the sensor measurement is non-linear in the state vector elements. If Ge and Se are used to denote glucose and scale factor estimates, respectively, then Ye=Se*Ge. Definitions of the above terms are provided in Table 3. When linearized using best estimates, the linearized measurement matrix H=[Se Ge] and is of the same functional form both before and after 20 hours.
  • [0076]
    [0076]FIG. 3D illustrates a measurement-update process of one embodiment of an optimal estimator. The measurement update sequence begins with the computation of the gain matrix, K(i). The difference between the actual sensor measurement and the best estimate of the measurement is computed: y(i)=Ym(i)−Se(i)*Ge(i). This difference, or residual, when multiplied by the gain matrix and added to the time-updated estimate produces the measurement-updated estimate.
  • [0077]
    The covariance matrix is then measurement updated, reflecting the level of uncertainty in the estimates following the processing of a measurement. In the glucose example, if a second measurement is available, such as a CBG, then the measurement sequence is again cycled through, starting with a new gain computation, and using the appropriate measurement matrix and new best estimate of the next measurement. Following the processing of all available measurements at the ith time epoch, the updated state vector and covariance matrix are then used to start the time update for the (i+1)th time epoch which begins the next cycle.
  • [0078]
    One embodiment of an estimation algorithm illustrating the initialization, the time update process, and the measurement update process discussed above is provided in Table 4. Table 4 is an algorithm programmed in the MATLAB language (from Math Works). This printout defines a working program and has been used to process a significant number of data sets. In the glucose example, the estimation results from the process of two data files, both gathered from the same patient, and taken about a month apart, are shown in FIGS. 4A, 4B, 5A, and 5B.
  • [0079]
    In one embodiment, sensor inputs are provided and processed every 5 minutes. Occasional CBGs are also provided. For example, two CBGs per day were processed by an estimator; and additional CBG values were used to judge estimator performance by comparing glucose estimates with actual CBG values not used by the estimator.
  • [0080]
    [0080]FIGS. 4A and 4B illustrate a first set of time history plots of optimal glucose estimates and CBG measurements with respect to time. FIG. 4A shows a time history of the real-time estimates of glucose (e.g., every 5 minutes) along with all available discrete CBGs.
  • [0081]
    [0081]FIG. 4B shows a time history of the glucose estimates along with CBGs that were processed. In this figure, the estimated glucose value took several rapid swings between approximately 48 hours and 58 hours. FIG. 4B indicates that only sensor measurements were processed during that interval and no CBGs were processed. However, the CBGs plotted in FIG. 4A indicate that the glucose estimates did tend to follow the excursions of the patient glucose levels.
  • [0082]
    [0082]FIGS. 5A and 5B illustrate a second set of time history plots of optimal glucose estimates and CBG measurements with respect to time. The time duration for these runs is about 4 days without patient inputs. Over this time period, the patient ate, slept, exercised, and took insulin injections. Dynamic models to account for these activities, much like the decaying scale factor, could be implemented and called into use upon command.
  • [0083]
    [0083]FIG. 6A is a block diagram of one embodiment of a patient health monitor. On example of an algorithm for the patient health monitor is in Table 4 which generates statistical test data based on Kalman filter residuals as well as test displays. In one embodiment, the patient health monitor generates real-time decisions and displays which are integrated with a Kalman filter. The patient health monitor allows the patient or medical staff to interact with a Kalman estimator and/or Kalman controller described herein.
  • [0084]
    In one embodiment, the patient health monitor provides insight into how well a Kalman filter is working through the filter residual that is the difference between the estimate of the measurement at the time the measurement is received and the actual measurement. In another embodiment, other checks are used from time to time, such as the CBGs in the glucose example described above. An example of another check on the status of a sensor is through the use of patient inputs or signals indicating that something is changing in a prescribed way and then noting whether or not the sensor is observing this change within prescribed uncertainties.
  • [0085]
    In one embodiment, the real-time displays and decisions of the patient health monitor uses some occasional outside checks but relies substantially on results of statistical testing performed on filter residuals. If estimates of the measurements are, on average, good (e.g., residuals are small and unbiased), then the estimator is generally working well, and vice versa. More specifically, elements of the covariance matrix can be used to construct statistical test applications.
  • [0086]
    For hospital applications, real-time displays of glucose estimates along with real-time displays of estimator performance test results can be important visual inputs to the medical staff. Requests for additional CBG measurements or the sounding of an alarm in the event glucose estimates exceed critical limits may also prove useful. In one embodiment, a reduced number of outputs is provided in relatively small estimators for individual use.
  • [0087]
    [0087]FIG. 6B illustrates one embodiment of a residual test data process in the patient health monitor. For example, the residual (y), covariance matrix (P), measurement matrix (H), and measurement noise matrix (R) are available from an estimator algorithm at each time epoch (i). If the estimator is operating properly, the sequence of residuals has the property of zero mean, white noise sequence, i.e., any two residuals taken at different times are uncorrelated (E[y(i)*y(j)]=0, for all j not equal to i). This condition provides a unique means for constructing statistical tests.
  • [0088]
    Visually, a time history plot of the residuals, Sy(i) in FIG. 6B, should appear random, zero mean, and unbaised. If they are summed over time, the deviation of the sum from zero should, on average, grow as the square root of time, as should its absolute value, ASy(i). The fact that E[y(i)*y(j)]=0, for i not equal to j, also means that the sum of the variances, SV(i) in FIG. 6B, which is easily computed, is equal to the variance of the sum of residuals for a properly performing estimator. The standard deviation of the sum of residuals, StdSV(i) also grows as the square root of time.
  • [0089]
    [0089]FIG. 6C illustrates one embodiment of a statistical test process in the patient health monitor. FIG. 6C defines statistical tests which can be constructed based on filter residual test data. One of these compares the absolute value of the sum of the residuals with the standard deviation of the sum of residuals. On average, the ASy(i) should be bounded by the StdSV(i). If not, this indicates that the deviations of Sy(i) are growing faster than that of a white noise sequence, implying degraded estimator performance.
  • [0090]
    Real-time displays of ASy(i) and StdSV(i) histories can provide a visual picture of estimator performance. An example is provided in FIGS. 7A and 7B which illustrate time history plots of residual test data with respect to measurement time. These two plots are one form of residual tests for the two sets of glucose estimation results provided in FIGS. 4A, 4B, 5A, and 5B respectively. In both cases, the sum of residuals are well behaved and was bounded by the Standard Deviation, Std, of the sum of residuals.
  • [0091]
    The example embodiment for the glucose application of test data, test generation, and test result display described above is implemented by the algorithm in Table 4. Other real-time quantitative tests can also be constructed using these data. Tests on individual residuals can be performed using individual variances. If a measurement is received which causes the residual to exceed a four signal level, for example, the action might be to emit a warning and request an immediate CBG measurement. Other tests are identified in FIG. 6C and will be evaluated as the system develops.
  • [0092]
    [0092]FIG. 6D illustrates one embodiment of an input/output interface in the patient health monitor. The patient health monitor provides a capability for the patient and/or staff to communicate and interact in real time with estimation and control processes using simple commands, visual displays, and audio outputs described above. Confidence levels in estimator performance can be established and a genuine interface established whereby the estimation and control processes could request additional information to check and insure confidence in estimates, physical sensors, and physical controllers. The staff can provide useful real-time inputs to augment this process.
  • [0093]
    [0093]FIG. 8 is a block diagram of one embodiment of a Kalman optimal stochastic control solution as applied to physiological processes. In one embodiment, the application includes both optimal stochastic regulator and optimal stochastic tracking control solutions. Tracking control involves a controlled variable following a reference value, constant or dynamic, as closely as possible. Control is applied to physiological processes, wherein a control gain is computed based upon optimization criteria which minimizes controlled variable errors while minimizing application of control based on cost weightings.
  • [0094]
    There is a duality between the computation of a Kalman estimator gain and a Kalman control gain. The Kalman estimator gain minimizes estimation error variances. The Kalman control gain minimizes variances of error between the controlled variables and the reference variables while minimizing the level of control applied. As a result, the optimal control function includes specification of the controlled variables and their associated costs as well as costs associated with the amount of control to be applied. For example, smaller control variable error costs and larger control application costs will allow the controlled variable to deviate farther from the reference, but with reduced application of control.
  • [0095]
    In one embodiment, linearization techniques described above in association with the Kalman estimator is applied to physiological nonlinear stochastic processes. For example, linearization about nominal values or about best estimates are provided by the Kalman estimator. Uncertain parameters associated with a controllable dispenser, or actuator, are included in an estimator state vector.
  • [0096]
    The optimal stochastic controller can use linear or nonlinear formulations and discrete or continuous time formulations. In one embodiment, the optimal stochastic controller is used with an optimal estimator described herein and/or an optimized decision and display function also described herein to form a closed loop system. The closed loop system works as an artificial pancreas when applied to a glucose problem in one embodiment.
  • [0097]
    [0097]FIG. 8 is a functional diagram showing a controllable dispenser, or pump, with the capability to secrete insulin and glucagon to control high and low glucose levels, respectively. In one embodiment of a closed loop system, an estimator and a controller share a state vector wherein the estimator estimates it and the controller controls designated elements of it. Unlike the estimator, the time varying gain computations for the controller is computationally intensive and may not be used in all applications. The controller includes time varying or steady state gain formulations.
  • [0098]
    [0098]FIG. 9A illustrates one embodiment of an optimal controller for the artificial pancreas. The glucose control problem is a tracking problem since the glucose level is controlled to a desired level which may either be constant or a function of time. In one embodiment, the dynamic process model includes a quantitative description of how glucose levels propagate, in time, as a function of insulin/glucagon secreted by the controllable pump. The dynamic process model is described by a system of first order differential or difference equations. Excluding the pump, much of the modeling for the glucose control is available through the estimator modeling development.
  • [0099]
    [0099]FIG. 9B illustrates one embodiment of a control model for a controller. In an example embodiment, the dynamic process model is described by three first order differential equations that are forced by a control variable, u. The dynamics of this process include a first order time lag and a scale factor associated with the pump, and a first order time lag and a scale factor associated with the physiological process. The model for the glucose sensors is the same as in the example glucose estimator embodiment. In the definition of the elements of the transition matrix, alpha g, s, and d are the inverse of the first order time lags associated with glucose, glucose sensor scale factor, and pump, respectively. Beta g is the glucose scale factor multiplied by alpha g. Delta t is the time interval between measurement/control application epochs. The controlled error is the difference between the estimate of glucose (provided by the estimator) and the glucose control point input.
  • [0100]
    In a controller command, Beta d is a pump scale factor multiplied by alpha d. The measurements are the same as for the example glucose estimator, except that the measurements contain an additional zero since the measurements are not functions of the variable insulin/glucagon.
  • [0101]
    The cost function, which is minimized by the optimal stochastic control, contains costs associated with the glucose error and the application of control. Choosing a value of Cu that is much larger than Cg will result in a relative gentle application of control. Another example embodiment would utilize a higher order model in which the first derivative of glucose would be included in the state vector, and included as a control variable. If a relatively large cost is associated with the first derivative relative to the glucose control point error, then the control will be very active when rapid changes in patient glucose occur while relatively gentle otherwise. Other example embodiments would include pump scale factor as a state vector element (uncertain parameter) as well as insulin/glucagon measurements to the estimator.
  • [0102]
    [0102]FIG. 9C illustrates one embodiment of a control algorithm based on the model defined in FIG. 9B. Using either a time varying gain or a pre-computed steady state gain, control is applied at each epoch based upon a difference between an estimate of a patient glucose level and a glucose control point. A control, u, is applied to a pump over each time interval, and a state vector is time updated as indicated in this Figure using the control variable, u, as a forcing function. Other time updates are performed in accordance with embodiments discussed above in association with estimator equations.
  • [0103]
    A potential problem in the application of closed loop control to that of physiological processes is due to potentially long time delays that may be de-stabilizing. These delays can be in the form of transport lags. A transport lag is the time between when control is applied and when the process action begins. An optimal technique for control using delay states is discussed in “Optimal Control of Linear Stochastic Systems with Process and Observation Time Delays” by E. J. Knobbe (Academic Press, Inc., 1989) and is hereby incorporated herein in its entirety by reference thereto. A discussion of principles developed for optimal control with process and observation time delays is provided in Table 5.
  • [0104]
    Although described above in connection with particular embodiments of the present invention, it should be understood that the descriptions of the embodiments are illustrative of the invention and are not intended to be limiting. Various modifications and applications may occur to those skilled in the art without departing from the true spirit and scope of the invention.
    TABLE 1
    SUMMARY OF CONTINUOUS-DISCRETE
    EXTENDED KALMAN FILTER
    System Model x _ . ( t ) = f _ ( x _ ( t ) , t ) + w _ ( t ) ; w _ ( t ) ~ N ( 0 _ , Q ( t ) )
    Figure US20030195404A1-20031016-M00001
    Measurement Model z _ k = h _ k ( x _ ( t k _ ) ) + v _ k ; k = 1 , 2 , ; v _ k ~ N ( 0 _ , R k )
    Figure US20030195404A1-20031016-M00002
    Initial Conditions x _ ( 0 ) ~ N ( x _ ^ o , P o )
    Figure US20030195404A1-20031016-M00003
    Other Assumptions E [ w _ ( t ) v k T ] = 0 for all k and all t
    Figure US20030195404A1-20031016-M00004
    State Estimate Propagation x _ ^ . ( t ) = f _ ( x _ ^ ( t ) , t )
    Figure US20030195404A1-20031016-M00005
    Error Covariance Propagation P . ( t ) = F ^ ( x _ ^ ( t ) , t ) P ( t ) + P ( t ) F T ( x _ ^ ( t ) , t ) + Q ( t )
    Figure US20030195404A1-20031016-M00006
    State Estimate Update x _ ^ k ( + ) = x _ ^ k ( - ) + K k [ z _ k - h _ k ( x _ ^ k ( - ) ) ]
    Figure US20030195404A1-20031016-M00007
    Error Covariance Update P k ( + ) = [ I - K k H k ( x _ ^ k ( - ) ) ] P k ( - )
    Figure US20030195404A1-20031016-M00008
    Gain Matrix K k = P k ( - ) H k T ( x _ ^ k ( - ) ) [ H k ( x _ ^ k ( - ) ) P k ( - ) H k T ( x _ ^ k ( - ) ) + R k ] - 1
    Figure US20030195404A1-20031016-M00009
    Definitions F ( x _ ^ ( t ) , t ) = f _ ( x _ ( t ) , t ) x _ ( t ) x _ ( t ) = x _ ^ ( t ) H k ( x _ ^ k ( - ) ) = h _ k ( x _ ( t k ) ) x _ ( t k ) x _ ( t k ) = x _ ^ k ( - )
    Figure US20030195404A1-20031016-M00010
  • [0105]
    [0105]
    TABLE 2
    SUMMARY OF CONTINUOUS-DISCRETE
    LINEARIZED KALMAN FILTER
    System Model x _ . ( t ) = f _ ( x _ ( t ) , t ) + w _ ( t ) ; w _ ( t ) ~ N ( 0 _ , Q ( t ) )
    Figure US20030195404A1-20031016-M00011
    Measurement Model z _ k = h _ k ( x _ ( t k _ ) ) + v _ k ; k = 1 , 2 , ; v _ k ~ N ( 0 _ , R k )
    Figure US20030195404A1-20031016-M00012
    Initial Conditions x _ ( 0 ) ~ N ( x _ ^ o , P o )
    Figure US20030195404A1-20031016-M00013
    Other Assumptions E [ w _ ( t ) v k T ] = 0 for all k and all t Nominal trajectory x _ _ ( t ) is available
    Figure US20030195404A1-20031016-M00014
    State Estimate Propagation x _ ^ . ( t ) = f _ ( x _ _ ( t ) , t ) + P ( x _ _ ( t ) , t ) [ x _ _ ( t ) - x _ _ ( t ) ]
    Figure US20030195404A1-20031016-M00015
    Error Covariance Propagation P . ( t ) = F ^ ( x _ ^ ( t ) , t ) P ( t ) + P ( t ) F T ( x _ ^ ( t ) , t ) + Q ( t )
    Figure US20030195404A1-20031016-M00016
    State Estimate Update x _ ^ k ( + ) = x _ ^ k ( - ) + K k [ z _ k - b _ k ( x _ _ ( t k ) ) - H k ( x _ _ ( t ) ) [ x _ ^ k ( - ) - x _ _ ( t k ) ] ]
    Figure US20030195404A1-20031016-M00017
    Error Covariance Update P k ( + ) = [ I - K k H k ( x _ ^ ( t k ) ) ] P k ( - )
    Figure US20030195404A1-20031016-M00018
    Gain Matrix K k = P k ( - ) H k T ( x _ ^ k ( - ) ) [ H k ( x _ ^ k ( - ) ) P k ( - ) H k T ( x _ ^ k ( - ) ) + R k ] - 1
    Figure US20030195404A1-20031016-M00019
    Definitions F ( x _ ^ ( t ) , t ) = f _ ( x _ ( t ) , t ) x _ ( t ) x _ ( t ) = x _ _ ( t ) H k ( x _ _ k ( t k ) ) = h _ k ( x _ ( t k ) ) x _ ( t k ) x _ ( t k ) = x _ _ k ( t k )
    Figure US20030195404A1-20031016-M00020
  • [0106]
    [0106]
    TABLE 3
    State Vector
    X, Xe, Xe(0): These symbols denote, respectively, the state vector, the best estimate (or optimal
    estimate) of the state vector, and the initial best estimate of the state vector. They contain both variables
    and parameters as defined above and, with regard to estimation, there are no distinctions.
    Dynamic Process Model
    dX = f(X,t), dXe = f(Xe,t): These symbols denote the time derivative of the state vector and estimated
    state vector, respectively. They represent a system of first order differential equations (or difference
    equations) which describe the manner in which the state elements propagate in time. The function, f, may
    be linear or nonlinear.
    Measurement Model
    Ym = h(X) + e, Ye = h(Xe): These symbols denote the actual measurement and the best estimate of the
    measurement, respectively. The function, h, defines the arbitrary, but known, way in which the state
    vector elements are related to the measurement, and e represents the sensor measurement error.
    Covariance Matrix
    P, P(0): Denotes, respectively, the matrix of variances and co-variances associated with the errors of each
    of the state variable estimates (within the estimated state vector) and their initial values,
    Transition Matrix
    A, A(0): Denotes the transition matrix, which is used to propagate the covariance matrix forward it time
    (time update), and it's initial value, respectively; in the linear case it is also used to time update the state
    vector estimate.
    Process Noise Matrix
    Q: Denotes the matrix of variances and co-variances associated with error growth uncertainty
    accumulated in the state variable estimates since the last measurement update,
    Measurement Matrix
    H, H(0): Denotes the measurement matrix and it's initial value, respectively. This matrix defines the
    linear functional relationship between the measurement and the state vector elements. If, the measurement
    model is linear, then H = h; if h is non-linear, then H is defined by linearizing h using partial derivatives
    or perturbation techniques.
    Measurement Noise Matrix
    R: Denotes the matrix of variances and co-variances associated with measurement error uncertainties.
    Kalman Gain Matrix
    K: Denotes the Kalman gain matrix which, when multiplied by the difference between the actual
    measurement, and the best estimate of the measurement, yields the estimated state correction. This
    estimated state correction, when added to the old best estimate, becomes the new best estimate.
    Estimated Measurement Error (Residual)
    y = Ym − Ye: Denotes the difference between the actual measurement and the best estimate of the
    measurement. This difference multiplied by the Kalman gain yields the correction to the previous state
    vector estimate.
  • [0107]
    [0107]
    TABLE 4
    % Optimal Glucose Estimator. Extended Kalman Filter; Computes Statistical Test Data for
    Patient Health Monitor
    %Ed_JYP_Estimator; Two-step scale-factor model, Exp = .999 for t>20; r=15{circumflex over ( )}2 for y<10 ;
    x=[150;.25]; hh=[1 0];p=[100{circumflex over ( )}2 0 ;0 .1{circumflex over ( )}2];a=[1 0 ; 0 1]; q=[20{circumflex over ( )}2 0 ; 0 .002{circumflex over ( )}2]; rr=15{circumflex over ( )}2;
    r= 5{circumflex over ( )}2; I=[1 0;0 1];
    load EdJY528.prn,
    [m,n]=size(EdJY528),
    t=EdJY528 1:, 1)/12;
    y=EdJY528(:,2);
    g=EdJY528(:,3);
    gm=EdJYS28(:,4);
    x=[gmf(1); .25];
    sz=0.0;
    SVZ = p(1,1)*K(2){circumflex over ( )}2 + p(2,2)*x(1){circumflex over ( )}2;
    for i = 1:m; . . .
    r = 5{circumflex over ( )}2; . . .
    zz = 0; . . .
    if y(i) < 10
    r = 15{circumflex over ( )}2; . . .
    end;
    if t(i) > 20 a =(1 0 ; 0 .999]; . . .
    end;
    p=a*p*a′+q; . . .
    x=a*x;. . .
    if gm(i) > 0
    k=p*hh*/(hh*p*hh*+rr); . . .
    zz=(gm(i)−x(1)); . . .
    x=x+k*zz; . . .
    p=(I−k*hh) *p; . . .
    end;
    h=[x(2) x(1)]; . . .
    k=p*h′/ (h*p*hh+r); . . .
    x=x+k*z; . . .
    p=(I−k*h) *p; . . .
    az=abs (z); . . .
    sz=sz+z;. . .
    asz = abs (sz); . . .
    VZ = p(1,1) *x(2){circumflex over ( )}2 + p(2,2)*x(1){circumflex over ( )}2 + 2*p(1,2)*x(1)*x(2)+ r ; . . .
    sigZ = sqrt(VZ); . . .
    SVZ = SVZ +VZ; . . .
    siqSZ = sqrt(SVZ); . . .
    VZZ = p(1.1) + rr; . . .
    sigZZ = sqrt(VZZ); . . .
    azz = abs(zz); . . .
    xhistory(i,1) = x(1); . . .
    xhistory(i,2) = x(2); . . .
    gmhistory =gm; . . .
    ghistory =g; . . .
    zhistory(i) =z; . . .
    sigsz_history(i) = sigSZ; . . .
    sigz_history(i) = 2*sigZ; . . .
    aszhistory(i) = asz; . . .
    azhistory(i) = az; . . .
    zzhistory(i) = zz; . . .
    sigzz_history(i) = 2*sigZZ; . . .
    azzhistory(i) = azz; . . .
    sig_history(i,1)=sqrt(p(1,1)); . . .
    sig_history(i,2)=sqrt(p(2,2)); . . .
    yhistory=y;. . .
    end;
    figure (1)
    plot(t,xhistory(:,2));
    xlabel (′ Measurement Time (hrs) ′);
    ylabel(′ Scale Factor Estimate; (ISIG Units/(mg/dl))′);
    title(′Scale Factor Estimate vs Time′);
    figure (2)
    plot (t, gmhistory (:), t,xhistory (:,1));
    xlabel(′Time (hrs)′);
    Ylabel(′Glucose Meas & Estimated Glucose; (mg/dl)′);
    title(′All Glucose Measurements & Estimated Glucose vs Time′);
    figure (3)
    plot (t,yhistory (:), t, zhistory(:));
    xlabel(′Time (hrs)′);
    Ylabel(′ISIG Meas & z Residual; (ISIG Units) ′);
    title(′ISIG Measurement & z residual vs Time′);
    figure (4)
    plot(t,xhistory(:,1),t,ghistory(:,1));
    xlabel(′ Time (hrs)′);
    ylabel(′Glucose & Estimated Glucose; (mg/dl)′);
    title(′Glucose Estimate & All Glucose CBGs vs Time′);
    figure (5)
    plot(t,sigzz_history(:),t,azzhistory(:));
    xlabel (′Time (hrs) ′);
    ylabel(′Abs(zz) Residual & two sigma(zz); (mg/dl) ′);
    title(′Residual Test: 2 Siqma(zz) & Abs(zz) Residual vs Time′);
    figure (6)
    plot(t,azhistory(:),t,sigz_history(:));
    xlabel(′Measurement Time (hrs)′);
    ylabel(′z Residual & Standard Deviation; (ISIG Units)′);
    title(′Residual Test Abs(z) & 2 Sigma(z) vs Time′);
    figure (7)
    plot(t,aszhistory(:),t,sigsz_history(:));
    xlabel(′ Measurement Time (hrs)′);
    ylabel(′ sz Residual & Sigma; (ISIG Units) ′);
    title(′Residual Test : Abs(sz) & Sigma(sz) vs Time′);
  • [0108]
    [0108]
    TABLE 5
    PROBLEM DEFINITION
    The general, discrete-time system representation with explicit
    process and observation time delays is given by
    x ( k + 1 ) = i = 1 q A i ( k ) X ( k + 1 - i ) + B ( k ) U ( k ) + W 1 ( k ) ,
    Figure US20030195404A1-20031016-M00021
    (1)
    Y ( k ) = j = 1 p C j ( k ) X ( k + 1 - j ) + W 2 ( k ) ,
    Figure US20030195404A1-20031016-M00022
    (2)
    where p and q are integers > 1; W1 and W2 are zero-mean
    white-noise sequences such that
    E { W 1 ( k ) W 1 T ( k ) } = V 1 ( k ) E { W 2 ( k ) W 2 T ( k ) } = V 2 ( k ) E { W 1 ( i ) W 1 T ( j ) } = 0 } i , j , k ;
    Figure US20030195404A1-20031016-M00023
    Y is an m × 1 observation vector; X is an n × 1 random state vector whose
    initial uncertainty is uncorrelated with W1 and W2 and with
    initial covariance Q0; and U is the control input vector. The
    objective is to find the control function (functional) U(k) for
    k = 1, 2, . . . that minimizes an expected quadratic cost function
    for the linear stochastic regulator defined by Eqs. (1) and
    (2). Because linear stochastic tracking problems can be formulated
    as linear stochastic regulator problems by combining the
    reference and plant models in an augmented system [3],
    this system representation applies equally to the
    tracking problem.
    PROBLEM FORMULATION AND SOLUTION
    The system representation defined by Eqs. (1) and (2) can be
    cast in stochastic regulator form by augmenting the state
    vector with the time-delayed states, that is,
    X _ ( k + 1 ) = A _ ( k ) X _ ( k ) + B _ ( k ) * U ( k ) + W _ 1 ( k ) ,
    Figure US20030195404A1-20031016-M00024
    (3)
    and
    Y ( k ) = C _ ( k ) X _ ( k ) + W 2 ( k )
    Figure US20030195404A1-20031016-M00025
    (4)
    A _ ( k ) = Δ [ 0 I 0 0 0 0 0 I A k ( k ) A 1 ( k ) ] , X _ ( k ) = Δ [ X ( k - h + 1 ) X ( k - h + 2 ) X ( k - 1 ) X ( k ) ] , B _ ( k ) = Δ [ 0 0 B ( k ) ] , W _ ( k ) = Δ [ 0 0 W 1 ( k ) ] , C _ ( k ) T = Δ [ C h ( k ) C h - 1 ( k ) C 2 ( k ) C 1 ( k ) ] ,
    Figure US20030195404A1-20031016-M00026
    and the dimensionality of the system is defined by h, where h = max(p, q)
    In Eq. (3), the control remains the same as in Eq. (1) because;
    physically, past states cannot be changed or controlled. In Eq. (4)
    the observation Y and the observation noise W2 also
    remain unchanged.
    In Eqs. (1) and (2), p and q are not, in general. equal. For example. if the
    observation is not a linear function of all the delayed states contained in {overscore (X)}.
    then h = q > p. and the appropriate (q − p) submatrices
    in {overscore (C)}. of Eq. (4). are set equal to zero. If the process
    evolution is not a linear function of all the delayed
    states contained in {overscore (X)}, then h = p > q, and the
    appropriate submatrices in {overscore (A)}. of Eq. (3). are set equal
    to zero. The dimensions of {overscore (B)} and {overscore (W)}1,in Eq. (3), must also
    be consistent with the integer h. Therefore, without loss of generality, the
    system defined by Eqs. (1) and (2) can be represented
    by the augmented system model described by Eqs. (3) and (4).
    Given that the control is to minimize the expected value of a quadratic cost
    function of the form,
    E { k = k 0 k 1 - 1 [ X _ ( k ) T R _ 1 ( k ) X _ ( k ) + U T ( k ) R 2 ( k ) U ( k ) ] + X _ ( k 1 ) P _ ( k 1 ) X _ ( k 1 ) } ,
    Figure US20030195404A1-20031016-M00027
    (5)
    then the separation principle applies [3]. Also, the optimal linear stochastic
    control of the augmented system is given by a deterministic, optimal linear
    controller with state input {overscore (X)} (or estimated state feedback),
    which is provided by an optimal one-step predictor using the
    augmented model [4]. That is,
    U ( k ) = - F _ ( k ) X _ ^ ( k ) ; k = k 0 , k 0 + 1 , , k 1 ,
    Figure US20030195404A1-20031016-M00028
    (6)
    where the control gain {overscore (F)} satisfies
    F _ ( k ) = { R 2 ( k ) + B _ T ( k ) [ R _ 1 ( k + 1 ) + P _ ( k + 1 ] B ( k ) } - 1 B T ( k ) [ R _ ( k + 1 ) + P ( k + 1 ) ] A _ ( k ) ;
    Figure US20030195404A1-20031016-M00029
    (7)
    the matrix {overscore (P)} satisfies the recursive matrix Riccati equation,
    P _ ( k ) = A _ 1 ( k ) [ R _ 1 ( k + 1 ) + P _ ( k + 1 ] [ A _ ( k ) - B _ ( k ) F _ ( k ) ] ;
    Figure US20030195404A1-20031016-M00030
    (8)
    the one - step predictor output X _ ^ is defined by
    Figure US20030195404A1-20031016-M00031
    X _ ^ ( k + 1 ) = A _ ( k ) X _ ^ ( k ) + B _ ( k ) U ( k ) + K _ ( k ) [ Y ( k ) - C _ ( k ) X _ ^ ( k ) ] ;
    Figure US20030195404A1-20031016-M00032
    (9)
    the estimator gain {overscore (K)} satisfies
    K _ ( k ) = A _ ( k ) Q _ ( k ) C _ T ( k ) [ C _ ( k ) Q _ ( k ) C _ T ( k ) + V 2 ( k ) ] - 1 ;
    Figure US20030195404A1-20031016-M00033
    (10)
    and the state estimation error covariance matrix {overscore (Q)} satisfies
    the recursive matrix Riccati equation,
    Q _ ( k + 1 ) = [ A _ ( k ) - K _ ( k ) C _ ( k ) ] Q _ ( k ) A _ T ( k ) + V _ 1 ( k ) .
    Figure US20030195404A1-20031016-M00034
    (11)
    The final value of {overscore (P)} used to “initialize” Eq. (8)
    (which is solved backward in time) is the final value defined in
    the quadratic cost function of Eq. (5), that is,
    {overscore (P)}(k1) = {overscore (P)}1. The initial value of {overscore (Q)} used to initialize Eq. (11) is the error
    covariance of the initial estimate of X, that is, {overscore (Q)}(0) = {overscore (Q)}0.
    If the system statistics defined in Eqs. (1) and (2) are gaussian,
    then the above solution is the optimal solution without qualification;
    if not, then it is the optimal linear control solution. The expected
    system performance is determined by analyzing the augmented system
    as a linear, stochastic regulator problem
    PRACTICAL APPLICATIONS
    From control gain Eqs. (7) and (8) and estimator gain
    Eqs. (10) and (11), it can be shown that the required dimensions of
    the controller and estimator are not, in general, equal. The
    dimensions of the control matrix Riccati equation (8) is determined
    by the number of delayed states in the process evolution, that
    is, {overscore (P)} has the dimensions of n · q × n · q.
    Consequently, for the special case of measurement delays only
    (q = 1), the controller implementation is unaffected.
    However, the dimensions of the estimator matrix Riccati equation (11) are
    determined by the maximum of p and q. Since h = max(p, q),
    then {overscore (Q)} has the dimensions n · h × n · h.
    For the general case, the optimal control is given by
    U ( k ) = - i = 1 q F i ( k ) X ^ ( k + 1 - i ) ,
    Figure US20030195404A1-20031016-M00035
    (12)
    where
    F _ ( k ) = Δ [ F q ( k ) F q - 1 ( k ) F 2 ( k ) F 1 ( k ) ] ,
    Figure US20030195404A1-20031016-M00036
    (13)
    and
    X _ ^ T ( k ) = Δ [ X ^ T ( k + 1 - h ) X ^ T ( k + 1 - q ) X ^ T ( k - 1 ) X ^ T ( k ) ] .
    Figure US20030195404A1-20031016-M00037
    (14)
    We note that, in Eq. (14), {circumflex over (X)}(k) is the one-step predicted
    value of the original system state vector; {circumflex over (X)}(k − 1) is the
    filtered value; {circumflex over (X)}(k − 2) is the one-step
    smoothed value; and, finally, {circumflex over (X)}(k + 1 − h) is
    the (h − 2)th smoothed value. Typically, the real-time computational
    requirements associated with the implementation of time-varying
    optimal control are always stressing due to
    the “backward-in-time” recursion that is required to obtain solutions {overscore (P)} of
    Eq. (8). However, in many high-accuracy applications, the {overscore (A)},
    {overscore (B)}, {overscore (R)}1, and R2
    matrices of the augmented system and cost function can be treated as time
    invariant over the time intervals of interest. Further,
    if the augmented system satisfies the relatively minor requirements
    of stabilizability and detectability, then the control gain
    {overscore (F)} will converge to a unique value such that the steady-
    state optimal control law is time invariant, asymptotically stable, and mini-
    mizes the quadratic cost function of Eq (5) as k1 → ∞. For this case, the
    steady-state gain matrix {overscore (F)}ss can be computed off-line and stored for real-
    time use; the real-time computations required to implement
    this steady-state control law are negligible.
    Usually, for tracking and regulator problems, the steady-state control
    gains and time-varying gains are such that the initial value of the
    time-varying gain is equal to the steady-state gain but is less than or
    equal to the steady-state gain as time progresses, that is,
    F _ ss F _ ( k ) for k o k k 1 .
    Figure US20030195404A1-20031016-M00038
    As a consequence, the steady-state gain tends to maintain the
    controlled state closer to the estimated state, but at the cost
    of control energy. If accuracy is the significant criterion,
    then the steady-state gain is not only easy to implement
    but also provides essentially equivalent or better accuracy.
    This, however, is not the case for the estimator gain, even though in most
    cases where linear steady-state optimal stochastic control is implemented,
    both the steady-state control and the estimator gains are used. For the es-
    timator, and the same general conditions as before, the initial time-varying
    estimator gain is usually significantly larger than the steady-state gain, to
    account for initial uncertainties in the knowledge of the system state.
    As time progresses, the time-varying gain converges to the steady-state
    gain, that is,
    K _ ss K _ ( k ) for k o k k 1 .
    Figure US20030195404A1-20031016-M00039
    Consequently, initial system performance is significantly degraded if Kss is
    used. In fact, if applied to a “linearized” system, the estimator can actually
    diverge given the initial small steady-state filter gains.
    Hence a good compromise between performance and computational
    complexity is to choose the steady-state controller with the time-varying
    estimator. Further, because the estimator matrix Riccati equation is solved
    forward in time, the computations associated with the time-varying
    filter gain are orders of magnitude less than with the time-varying
    control gain and can usually be implemented in real time.
    Although the computations associated with the augmented system es-
    timator are significantly increased because of the increased
    dimensions, some simplifications can be made. The estimator Riccati
    equation can be separated into a time update and a measurement
    update, where the time update for the augmented system becomes
    primarily one of data transfer. If {overscore (Q)}, from Eq. (11),
    is defined as
    Q ( k ) = [ Q 1 , 1 ( k ) Q 1 , 2 ( k ) Q 1 , h ( k ) Q 2 , 1 ( k ) Q 2 , 2 ( k ) Q h , 1 ( k ) Q h , h ( k ) ] ,
    Figure US20030195404A1-20031016-M00040
    (15)
    then, for the special case where q = 1 and p ≧ 2,
    the time update becomes
    Q i , j ( k + 1 ) = Q i + 1 , j + 1 ( k ) Q i , P ( k + 1 ) = Q i + 1 , P ( k ) A 1 T ( k ) } i , j = 1 , , p - 1 Q p , p ( k + 1 ) = A 1 ( k ) Q p , p ( k ) A 1 T ( k ) + V 1 ( k ) } .
    Figure US20030195404A1-20031016-M00041
    (16)
    For the worst case, where q > p > I, the time update is given by
    Q i , j ( k + 1 ) = Q i + 1 , j + 1 ( k ) , i , j = 1 , , q - 1 , Q i , q ( k + 1 ) = j = 1 q Q i , j ( k ) A ( q + 1 ) - j T ( k ) , i = 1 , , q - 1 , Q q , q ( k + 1 ) = i = 1 q j = 1 q A ( q + 1 ) - i ( k ) Q i , j ( k ) A ( q + 1 ) - j T ( k ) + V 1 ( k ) } .
    Figure US20030195404A1-20031016-M00042
    (17)
    In practice, another computational simplification results because rarely, if
    ever, is the actual system measurement a function of every time-delayed
    state element, and likewise for the actual system process model. Hence the
    submatrices Ai and Ci (for i > 1) in {overscore (A)} and {overscore (C)}, respectively, are usually of
    significantly reduced dimension. This, in turn, significantly reduces the
    dimensions of the augmented system model.
    We note that the iteration interval Δt (implied in the discrete-time system
    representation) or some integer number of Δt's should be set equal to
    the time delay. For variable time delays, it may be advantageous to use (a)
    variable iteration intervals for the estimator, (b) fixed iteration intervals
    for the controller, and (c) variable-time updates of the state estimate to
    time synch the estimator output with the controller input.
    Finally, for the analogous continuous-time problem, the filter equation
    becomes a partial differential equation with a boundary condition, and the
    covanance equation becomes a partial differential matrix equation with
    three boundary conditions (see [2]). Consequently, the most practical
    control solution is obtained by discretizing the continuous-time system
    representation and then applying the approach of Section III. One
    technique for discretizing the continuous-time representation is by
    using the Z transform method; see, for example, [5]. Using a scalar
    differential equation with one delayed slate as an example, we have
    X . ( t ) = i = 0 1 a i X ( t - i Δt ) + U ( t ) .
    Figure US20030195404A1-20031016-M00043
    (18)
    If we assume that the output solution X(t) is sampled in discrete time, and
    if the system process can be reasonably approximated by a continuous
    system in which {dot over (X)} is driven by the output of a high-
    frequency sampling of the right side of Eq. (18), then the
    discrete-time process model is given by
    X ( k + 1 ) = ( 1 + a 0 Δt ) X ( k ) + ( a 1 Δt ) X ( k - Δt ) + ( Δt ) U ( k ) .
    Figure US20030195404A1-20031016-M00044
    (19)
    The approximate discrete-time solution to Eq. (18), which is given by
    Eq. (19), is now in a form consistent with Eq. (1) of Section II, and the ap-
    proach of Section III can be applied.

Claims (4)

    What is claimed is:
  1. 1. A method for close-loop control of a physiological parameter comprising the acts of:
    obtaining a measurement of the physiological parameter from a patient;
    providing the measurement to an optimal estimator in real time, wherein the optimal estimator outputs a best estimate of the physiological parameter in real time based on the measurement;
    providing the best estimate of the physiological parameter to an optimal controller in real time, wherein the optimal controller outputs a control command in real time based on the best estimate of the physiological parameter and a control reference; and
    providing the control command to an actuator, wherein the actuator provides an output to adjust the physiological parameter.
  2. 2. The method of claim 1, wherein the measurement is obtained using a sensor.
  3. 3. The method of claim 1, wherein the optimal estimator is implemented using a linearized Kalman algorithm.
  4. 4. The method of claim 1, wherein the control reference is provided by a patient health monitor.
US10417438 2000-09-22 2003-04-16 Method and apparatus for real-time control of physiological parameters Abandoned US20030195404A1 (en)

Priority Applications (3)

Application Number Priority Date Filing Date Title
US23463200 true 2000-09-22 2000-09-22
US09960855 US6572545B2 (en) 2000-09-22 2001-09-21 Method and apparatus for real-time control of physiological parameters
US10417438 US20030195404A1 (en) 2000-09-22 2003-04-16 Method and apparatus for real-time control of physiological parameters

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US10417438 US20030195404A1 (en) 2000-09-22 2003-04-16 Method and apparatus for real-time control of physiological parameters

Related Parent Applications (1)

Application Number Title Priority Date Filing Date
US09960855 Continuation US6572545B2 (en) 2000-09-22 2001-09-21 Method and apparatus for real-time control of physiological parameters

Publications (1)

Publication Number Publication Date
US20030195404A1 true true US20030195404A1 (en) 2003-10-16

Family

ID=22882159

Family Applications (3)

Application Number Title Priority Date Filing Date
US09960855 Expired - Fee Related US6572545B2 (en) 2000-09-22 2001-09-21 Method and apparatus for real-time control of physiological parameters
US09960846 Expired - Fee Related US6575905B2 (en) 2000-09-22 2001-09-21 Method and apparatus for real-time estimation of physiological parameters
US10417438 Abandoned US20030195404A1 (en) 2000-09-22 2003-04-16 Method and apparatus for real-time control of physiological parameters

Family Applications Before (2)

Application Number Title Priority Date Filing Date
US09960855 Expired - Fee Related US6572545B2 (en) 2000-09-22 2001-09-21 Method and apparatus for real-time control of physiological parameters
US09960846 Expired - Fee Related US6575905B2 (en) 2000-09-22 2001-09-21 Method and apparatus for real-time estimation of physiological parameters

Country Status (2)

Country Link
US (3) US6572545B2 (en)
WO (1) WO2002024065A1 (en)

Cited By (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2005081171A2 (en) * 2004-02-19 2005-09-01 Edward Henry Mathews Insulin bolus calculator for mobile communication device
WO2008057384A2 (en) * 2006-11-02 2008-05-15 The University Of North Carolina At Chapel Hill Methods and systems for determining an intravenous insulin infusion rate
US20080214919A1 (en) * 2006-12-26 2008-09-04 Lifescan, Inc. System and method for implementation of glycemic control protocols
US20100249561A1 (en) * 2007-06-21 2010-09-30 University Of Virginia Patent Foundation LQG Artificial Pancreas Control System and Related Method
US20110238350A1 (en) * 2010-03-29 2011-09-29 Commissariat A L'energie Atomique Et Aux Energies Alternatives Calibrating method and system, recording medium for this method
US20110264378A1 (en) * 2008-11-26 2011-10-27 University Of Virginia Patent Foundation Method, System, and Computer Program Product For Tracking of Blood Glucose Variability in Diabetes
US20110282321A1 (en) * 2007-01-31 2011-11-17 Medtronic Minimed, Inc. Model predictive method and system for controlling and supervising insulin infusion
US8417311B2 (en) 2008-09-12 2013-04-09 Optiscan Biomedical Corporation Fluid component analysis system and method for glucose monitoring and control
US8449524B2 (en) 2007-10-10 2013-05-28 Optiscan Biomedical Corporation Fluid component analysis systems and methods for glucose monitoring and control
WO2017136218A1 (en) * 2016-02-01 2017-08-10 Dexcom, Inc. System and method for decision support using lifestyle factors

Families Citing this family (233)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6036924A (en) 1997-12-04 2000-03-14 Hewlett-Packard Company Cassette of lancet cartridges for sampling blood
US6391005B1 (en) 1998-03-30 2002-05-21 Agilent Technologies, Inc. Apparatus and method for penetration with shaft having a sensor for sensing penetration depth
US6175752B1 (en) 1998-04-30 2001-01-16 Therasense, Inc. Analyte monitoring device and methods of use
US8480580B2 (en) 1998-04-30 2013-07-09 Abbott Diabetes Care Inc. Analyte monitoring device and methods of use
US9066695B2 (en) 1998-04-30 2015-06-30 Abbott Diabetes Care Inc. Analyte monitoring device and methods of use
US8688188B2 (en) 1998-04-30 2014-04-01 Abbott Diabetes Care Inc. Analyte monitoring device and methods of use
US8465425B2 (en) 1998-04-30 2013-06-18 Abbott Diabetes Care Inc. Analyte monitoring device and methods of use
US8346337B2 (en) 1998-04-30 2013-01-01 Abbott Diabetes Care Inc. Analyte monitoring device and methods of use
US8974386B2 (en) 1998-04-30 2015-03-10 Abbott Diabetes Care Inc. Analyte monitoring device and methods of use
US6430525B1 (en) * 2000-06-05 2002-08-06 Masimo Corporation Variable mode averager
WO2002024065A1 (en) * 2000-09-22 2002-03-28 Knobbe, Lim & Buckingham Method and apparatus for real-time estimation and control of pysiological parameters
US8641644B2 (en) 2000-11-21 2014-02-04 Sanofi-Aventis Deutschland Gmbh Blood testing apparatus having a rotatable cartridge with multiple lancing elements and testing means
US6560471B1 (en) 2001-01-02 2003-05-06 Therasense, Inc. Analyte monitoring device and methods of use
US7892183B2 (en) 2002-04-19 2011-02-22 Pelikan Technologies, Inc. Method and apparatus for body fluid sampling and analyte sensing
WO2002078512A8 (en) 2001-04-02 2004-12-02 Therasense Inc Blood glucose tracking apparatus and methods
US7674232B2 (en) 2002-04-19 2010-03-09 Pelikan Technologies, Inc. Method and apparatus for penetrating tissue
US9795334B2 (en) 2002-04-19 2017-10-24 Sanofi-Aventis Deutschland Gmbh Method and apparatus for penetrating tissue
US7316700B2 (en) 2001-06-12 2008-01-08 Pelikan Technologies, Inc. Self optimizing lancing device with adaptation means to temporal variations in cutaneous properties
US7491178B2 (en) 2002-04-19 2009-02-17 Pelikan Technologies, Inc. Method and apparatus for penetrating tissue
US7547287B2 (en) 2002-04-19 2009-06-16 Pelikan Technologies, Inc. Method and apparatus for penetrating tissue
US7226461B2 (en) 2002-04-19 2007-06-05 Pelikan Technologies, Inc. Method and apparatus for a multi-use body fluid sampling device with sterility barrier release
US7331931B2 (en) 2002-04-19 2008-02-19 Pelikan Technologies, Inc. Method and apparatus for penetrating tissue
US7291117B2 (en) 2002-04-19 2007-11-06 Pelikan Technologies, Inc. Method and apparatus for penetrating tissue
US7232451B2 (en) 2002-04-19 2007-06-19 Pelikan Technologies, Inc. Method and apparatus for penetrating tissue
US7682318B2 (en) 2001-06-12 2010-03-23 Pelikan Technologies, Inc. Blood sampling apparatus and method
US8221334B2 (en) 2002-04-19 2012-07-17 Sanofi-Aventis Deutschland Gmbh Method and apparatus for penetrating tissue
US8267870B2 (en) 2002-04-19 2012-09-18 Sanofi-Aventis Deutschland Gmbh Method and apparatus for body fluid sampling with hybrid actuation
US9248267B2 (en) 2002-04-19 2016-02-02 Sanofi-Aventis Deustchland Gmbh Tissue penetration device
US7699791B2 (en) 2001-06-12 2010-04-20 Pelikan Technologies, Inc. Method and apparatus for improving success rate of blood yield from a fingerstick
US7717863B2 (en) 2002-04-19 2010-05-18 Pelikan Technologies, Inc. Method and apparatus for penetrating tissue
US7229458B2 (en) 2002-04-19 2007-06-12 Pelikan Technologies, Inc. Method and apparatus for penetrating tissue
US8784335B2 (en) 2002-04-19 2014-07-22 Sanofi-Aventis Deutschland Gmbh Body fluid sampling device with a capacitive sensor
US7648468B2 (en) 2002-04-19 2010-01-19 Pelikon Technologies, Inc. Method and apparatus for penetrating tissue
US7371247B2 (en) 2002-04-19 2008-05-13 Pelikan Technologies, Inc Method and apparatus for penetrating tissue
US9314194B2 (en) 2002-04-19 2016-04-19 Sanofi-Aventis Deutschland Gmbh Tissue penetration device
US7901362B2 (en) 2002-04-19 2011-03-08 Pelikan Technologies, Inc. Method and apparatus for penetrating tissue
US7981056B2 (en) 2002-04-19 2011-07-19 Pelikan Technologies, Inc. Methods and apparatus for lancet actuation
WO2002100460A3 (en) 2001-06-12 2003-05-08 Don Alden Electric lancet actuator
US7041068B2 (en) 2001-06-12 2006-05-09 Pelikan Technologies, Inc. Sampling module device and method
US7909778B2 (en) 2002-04-19 2011-03-22 Pelikan Technologies, Inc. Method and apparatus for penetrating tissue
US9226699B2 (en) 2002-04-19 2016-01-05 Sanofi-Aventis Deutschland Gmbh Body fluid sampling module with a continuous compression tissue interface surface
US8579831B2 (en) 2002-04-19 2013-11-12 Sanofi-Aventis Deutschland Gmbh Method and apparatus for penetrating tissue
US7297122B2 (en) 2002-04-19 2007-11-20 Pelikan Technologies, Inc. Method and apparatus for penetrating tissue
US8337419B2 (en) 2002-04-19 2012-12-25 Sanofi-Aventis Deutschland Gmbh Tissue penetration device
US9427532B2 (en) 2001-06-12 2016-08-30 Sanofi-Aventis Deutschland Gmbh Tissue penetration device
EP1404235A4 (en) 2001-06-12 2008-08-20 Pelikan Technologies Inc Method and apparatus for lancet launching device integrated onto a blood-sampling cartridge
US7976476B2 (en) 2002-04-19 2011-07-12 Pelikan Technologies, Inc. Device and method for variable speed lancet
US7344507B2 (en) 2002-04-19 2008-03-18 Pelikan Technologies, Inc. Method and apparatus for lancet actuation
US7451126B2 (en) * 2001-10-18 2008-11-11 Omron Corporation State space navigation system, user system and business methods for machine to machine business
US9282925B2 (en) 2002-02-12 2016-03-15 Dexcom, Inc. Systems and methods for replacing signal artifacts in a glucose sensor data stream
US8702624B2 (en) 2006-09-29 2014-04-22 Sanofi-Aventis Deutschland Gmbh Analyte measurement device with a single shot actuator
CA2484265C (en) * 2002-05-06 2012-08-07 Becton, Dickinson And Company Method and device for controlling drug pharmacokinetics
US8423113B2 (en) 2003-07-25 2013-04-16 Dexcom, Inc. Systems and methods for processing sensor data
US8260393B2 (en) 2003-07-25 2012-09-04 Dexcom, Inc. Systems and methods for replacing signal data artifacts in a glucose sensor data stream
US8574895B2 (en) 2002-12-30 2013-11-05 Sanofi-Aventis Deutschland Gmbh Method and apparatus using optical techniques to measure analyte levels
US7016715B2 (en) * 2003-01-13 2006-03-21 Nellcorpuritan Bennett Incorporated Selection of preset filter parameters based on signal quality
US6949816B2 (en) 2003-04-21 2005-09-27 Motorola, Inc. Semiconductor component having first surface area for electrically coupling to a semiconductor chip and second surface area for electrically coupling to a substrate, and method of manufacturing same
US20040253736A1 (en) * 2003-06-06 2004-12-16 Phil Stout Analytical device with prediction module and related methods
US7850621B2 (en) 2003-06-06 2010-12-14 Pelikan Technologies, Inc. Method and apparatus for body fluid sampling and analyte sensing
US8066639B2 (en) 2003-06-10 2011-11-29 Abbott Diabetes Care Inc. Glucose measuring device for use in personal area network
US8886273B2 (en) 2003-08-01 2014-11-11 Dexcom, Inc. Analyte sensor
US8275437B2 (en) 2003-08-01 2012-09-25 Dexcom, Inc. Transcutaneous analyte sensor
US8369919B2 (en) 2003-08-01 2013-02-05 Dexcom, Inc. Systems and methods for processing sensor data
US8160669B2 (en) 2003-08-01 2012-04-17 Dexcom, Inc. Transcutaneous analyte sensor
US7933639B2 (en) 2003-08-01 2011-04-26 Dexcom, Inc. System and methods for processing analyte sensor data
US7774145B2 (en) 2003-08-01 2010-08-10 Dexcom, Inc. Transcutaneous analyte sensor
US8761856B2 (en) 2003-08-01 2014-06-24 Dexcom, Inc. System and methods for processing analyte sensor data
US8886272B2 (en) 2004-07-13 2014-11-11 Dexcom, Inc. Analyte sensor
US8845536B2 (en) 2003-08-01 2014-09-30 Dexcom, Inc. Transcutaneous analyte sensor
US20100168542A1 (en) 2003-08-01 2010-07-01 Dexcom, Inc. System and methods for processing analyte sensor data
US7778680B2 (en) 2003-08-01 2010-08-17 Dexcom, Inc. System and methods for processing analyte sensor data
US9247901B2 (en) 2003-08-22 2016-02-02 Dexcom, Inc. Systems and methods for replacing signal artifacts in a glucose sensor data stream
US8010174B2 (en) 2003-08-22 2011-08-30 Dexcom, Inc. Systems and methods for replacing signal artifacts in a glucose sensor data stream
US8233959B2 (en) 2003-08-22 2012-07-31 Dexcom, Inc. Systems and methods for processing analyte sensor data
DE10343863A1 (en) * 2003-09-23 2005-04-14 Roche Diagnostics Gmbh Method and apparatus for continuously monitoring the concentration of an analyte
WO2005033659A3 (en) 2003-09-29 2007-01-18 Pelikan Technologies Inc Method and apparatus for an improved sample capture device
WO2005037095A1 (en) 2003-10-14 2005-04-28 Pelikan Technologies, Inc. Method and apparatus for a variable user interface
US20050119866A1 (en) * 2003-11-14 2005-06-02 Zaleski John R. Medical parameter processing system
US7519408B2 (en) 2003-11-19 2009-04-14 Dexcom, Inc. Integrated receiver for continuous analyte sensor
US8287453B2 (en) 2003-12-05 2012-10-16 Dexcom, Inc. Analyte sensor
EP2239567B1 (en) 2003-12-05 2015-09-02 DexCom, Inc. Calibration techniques for a continuous analyte sensor
EP1711791B1 (en) 2003-12-09 2014-10-15 DexCom, Inc. Signal processing for continuous analyte sensor
WO2005065414A3 (en) 2003-12-31 2005-12-29 Pelikan Technologies Inc Method and apparatus for improving fluidic flow and sample capture
US20050182500A1 (en) * 2004-02-17 2005-08-18 Continuous Control Solutions, Inc. Time delay definition
US7591801B2 (en) 2004-02-26 2009-09-22 Dexcom, Inc. Integrated delivery device for continuous glucose sensor
US8808228B2 (en) 2004-02-26 2014-08-19 Dexcom, Inc. Integrated medicament delivery device for use with continuous analyte sensor
US8792955B2 (en) 2004-05-03 2014-07-29 Dexcom, Inc. Transcutaneous analyte sensor
EP1751546A2 (en) 2004-05-20 2007-02-14 Albatros Technologies GmbH &amp; Co. KG Printable hydrogel for biosensors
EP1765194A4 (en) 2004-06-03 2010-09-29 Pelikan Technologies Inc Method and apparatus for a fluid sampling device
WO2006001797A1 (en) 2004-06-14 2006-01-05 Pelikan Technologies, Inc. Low pain penetrating
US7755503B2 (en) * 2004-06-16 2010-07-13 Dell Products L.P. System and method for error messaging of an incorrect information handling system graphics cable connection
US7783333B2 (en) 2004-07-13 2010-08-24 Dexcom, Inc. Transcutaneous medical device with variable stiffness
US7497827B2 (en) 2004-07-13 2009-03-03 Dexcom, Inc. Transcutaneous analyte sensor
US8565848B2 (en) 2004-07-13 2013-10-22 Dexcom, Inc. Transcutaneous analyte sensor
EP2327984B8 (en) * 2004-07-13 2015-04-22 DexCom, Inc. Transcutaneous analyte sensor
US8452368B2 (en) 2004-07-13 2013-05-28 Dexcom, Inc. Transcutaneous analyte sensor
US9247900B2 (en) 2004-07-13 2016-02-02 Dexcom, Inc. Analyte sensor
US20060016700A1 (en) 2004-07-13 2006-01-26 Dexcom, Inc. Transcutaneous analyte sensor
US20080027679A1 (en) * 2004-07-21 2008-01-31 Dror Shklarski Wearable Device, System and Method for Measuring Physiological and/or Environmental Parameters
US8396670B2 (en) * 2004-08-16 2013-03-12 Venture Milling, Inc. Process, system and method for improving the determination of digestive effects upon an ingestable substance
FR2874807B1 (en) * 2004-09-03 2006-11-10 Memscap Sa An analysis of the physical and chemical properties of the skin
WO2006024672A1 (en) * 2004-09-03 2006-03-09 Novo Nordisk A/S System and method for estimating the glucose concentration in blood
US7608042B2 (en) * 2004-09-29 2009-10-27 Intellidx, Inc. Blood monitoring system
US20070191716A1 (en) * 2004-09-29 2007-08-16 Daniel Goldberger Blood monitoring system
US20060229531A1 (en) * 2005-02-01 2006-10-12 Daniel Goldberger Blood monitoring system
US20060069436A1 (en) * 2004-09-30 2006-03-30 Depuy Spine, Inc. Trial disk implant
US8652831B2 (en) 2004-12-30 2014-02-18 Sanofi-Aventis Deutschland Gmbh Method and apparatus for analyte measurement test time
US7822454B1 (en) 2005-01-03 2010-10-26 Pelikan Technologies, Inc. Fluid sampling device with improved analyte detecting member configuration
JP2008526443A (en) 2005-01-13 2008-07-24 ウェルチ・アリン・インコーポレーテッド Vital signs monitor
US7545272B2 (en) 2005-02-08 2009-06-09 Therasense, Inc. RF tag on test strips, test strip vials and boxes
US7920906B2 (en) 2005-03-10 2011-04-05 Dexcom, Inc. System and methods for processing analyte sensor data for sensor calibration
US7509156B2 (en) * 2005-05-18 2009-03-24 Clarian Health Partners, Inc. System for managing glucose levels in patients with diabetes or hyperglycemia
US8880138B2 (en) 2005-09-30 2014-11-04 Abbott Diabetes Care Inc. Device for channeling fluid and methods of use
US20070088271A1 (en) * 2005-10-18 2007-04-19 Richards Cynthia C Medication device
US7766829B2 (en) 2005-11-04 2010-08-03 Abbott Diabetes Care Inc. Method and system for providing basal profile modification in analyte monitoring and management systems
US20070123801A1 (en) * 2005-11-28 2007-05-31 Daniel Goldberger Wearable, programmable automated blood testing system
US20080200838A1 (en) * 2005-11-28 2008-08-21 Daniel Goldberger Wearable, programmable automated blood testing system
EP1954184B1 (en) * 2005-11-29 2017-10-11 PhysIQ Inc. Residual-based monitoring of human health
US8133178B2 (en) 2006-02-22 2012-03-13 Dexcom, Inc. Analyte sensor
US7826879B2 (en) 2006-02-28 2010-11-02 Abbott Diabetes Care Inc. Analyte sensors and methods of use
US7620438B2 (en) 2006-03-31 2009-11-17 Abbott Diabetes Care Inc. Method and system for powering an electronic device
US7801582B2 (en) 2006-03-31 2010-09-21 Abbott Diabetes Care Inc. Analyte monitoring and management system and methods therefor
US8226891B2 (en) 2006-03-31 2012-07-24 Abbott Diabetes Care Inc. Analyte monitoring devices and methods therefor
US20070243567A1 (en) * 2006-04-13 2007-10-18 Syhhong Chang Beta cell mimicking control algorithm for artificial pancreas
US8092385B2 (en) * 2006-05-23 2012-01-10 Intellidx, Inc. Fluid access interface
US20090209938A1 (en) * 2006-05-29 2009-08-20 Wristop Technologies Oy Apparatus and method for dosing drug and wireless remote control of a drug pump
US20080071157A1 (en) 2006-06-07 2008-03-20 Abbott Diabetes Care, Inc. Analyte monitoring system and method
CN101500628B (en) * 2006-06-13 2013-07-03 康尔福盛303有限公司 System and method for optimizing control of PCA and PCEA system
EP1875933A1 (en) * 2006-07-06 2008-01-09 Debiotech S.A. Medical device for delivery of a solution
US7653425B2 (en) 2006-08-09 2010-01-26 Abbott Diabetes Care Inc. Method and system for providing calibration of an analyte sensor in an analyte monitoring system
US7618369B2 (en) * 2006-10-02 2009-11-17 Abbott Diabetes Care Inc. Method and system for dynamically updating calibration parameters for an analyte sensor
US8364231B2 (en) 2006-10-04 2013-01-29 Dexcom, Inc. Analyte sensor
US8388534B2 (en) * 2006-10-11 2013-03-05 Samsung Electronics Co., Ltd. Apparatus for providing skin care information by measuring skin moisture content and method and medium for the same
US20080306353A1 (en) * 2006-11-03 2008-12-11 Douglas Joel S Calculation device for metabolic control of critically ill and/or diabetic patients
US8732188B2 (en) 2007-02-18 2014-05-20 Abbott Diabetes Care Inc. Method and system for providing contextual based medication dosage determination
US8930203B2 (en) 2007-02-18 2015-01-06 Abbott Diabetes Care Inc. Multi-function analyte test device and methods therefor
US9636450B2 (en) 2007-02-19 2017-05-02 Udo Hoss Pump system modular components for delivering medication and analyte sensing at seperate insertion sites
US8123686B2 (en) 2007-03-01 2012-02-28 Abbott Diabetes Care Inc. Method and apparatus for providing rolling data in communication systems
US9204827B2 (en) 2007-04-14 2015-12-08 Abbott Diabetes Care Inc. Method and apparatus for providing data processing and control in medical communication system
EP2137637A4 (en) * 2007-04-14 2012-06-20 Abbott Diabetes Care Inc Method and apparatus for providing data processing and control in medical communication system
CA2683959C (en) 2007-04-14 2017-08-29 Abbott Diabetes Care Inc. Method and apparatus for providing data processing and control in medical communication system
US9008743B2 (en) 2007-04-14 2015-04-14 Abbott Diabetes Care Inc. Method and apparatus for providing data processing and control in medical communication system
US7768387B2 (en) 2007-04-14 2010-08-03 Abbott Diabetes Care Inc. Method and apparatus for providing dynamic multi-stage signal amplification in a medical device
US7928850B2 (en) 2007-05-08 2011-04-19 Abbott Diabetes Care Inc. Analyte monitoring system and methods
US8461985B2 (en) 2007-05-08 2013-06-11 Abbott Diabetes Care Inc. Analyte monitoring system and methods
US8665091B2 (en) 2007-05-08 2014-03-04 Abbott Diabetes Care Inc. Method and device for determining elapsed sensor life
US8456301B2 (en) 2007-05-08 2013-06-04 Abbott Diabetes Care Inc. Analyte monitoring system and methods
US8260558B2 (en) 2007-05-14 2012-09-04 Abbott Diabetes Care Inc. Method and apparatus for providing data processing and control in a medical communication system
US8600681B2 (en) 2007-05-14 2013-12-03 Abbott Diabetes Care Inc. Method and apparatus for providing data processing and control in a medical communication system
US9125548B2 (en) 2007-05-14 2015-09-08 Abbott Diabetes Care Inc. Method and apparatus for providing data processing and control in a medical communication system
US8239166B2 (en) 2007-05-14 2012-08-07 Abbott Diabetes Care Inc. Method and apparatus for providing data processing and control in a medical communication system
US8103471B2 (en) 2007-05-14 2012-01-24 Abbott Diabetes Care Inc. Method and apparatus for providing data processing and control in a medical communication system
US8140312B2 (en) 2007-05-14 2012-03-20 Abbott Diabetes Care Inc. Method and system for determining analyte levels
US8560038B2 (en) 2007-05-14 2013-10-15 Abbott Diabetes Care Inc. Method and apparatus for providing data processing and control in a medical communication system
US8444560B2 (en) 2007-05-14 2013-05-21 Abbott Diabetes Care Inc. Method and apparatus for providing data processing and control in a medical communication system
EP2152350A4 (en) 2007-06-08 2013-03-27 Dexcom Inc Integrated medicament delivery device for use with continuous analyte sensor
EP2006786B1 (en) * 2007-06-18 2018-05-09 Roche Diabetes Care GmbH Method and glucose monitoring system for monitoring individual metabolic response and for generating nutritional feedback
US8834366B2 (en) 2007-07-31 2014-09-16 Abbott Diabetes Care Inc. Method and apparatus for providing analyte sensor calibration
US20090143725A1 (en) * 2007-08-31 2009-06-04 Abbott Diabetes Care, Inc. Method of Optimizing Efficacy of Therapeutic Agent
DE102007046864A1 (en) * 2007-09-28 2009-04-09 Endress + Hauser Conducta Gesellschaft für Mess- und Regeltechnik mbH + Co. KG Measured value plausibility and quality evaluating method for e.g. control circuit, involves forming and evaluating derivative of measured value according to time, where measured value is compared with predefined warning limit value
US9452258B2 (en) * 2007-10-09 2016-09-27 Dexcom, Inc. Integrated insulin delivery system with continuous glucose sensor
GB0719969D0 (en) * 2007-10-12 2007-11-21 Cambridge Entpr Ltd Substance monitoring and control in human or animal bodies
US8374668B1 (en) 2007-10-23 2013-02-12 Abbott Diabetes Care Inc. Analyte sensor with lag compensation
US8409093B2 (en) 2007-10-23 2013-04-02 Abbott Diabetes Care Inc. Assessing measures of glycemic variability
US8377031B2 (en) * 2007-10-23 2013-02-19 Abbott Diabetes Care Inc. Closed loop control system with safety parameters and methods
US8417312B2 (en) 2007-10-25 2013-04-09 Dexcom, Inc. Systems and methods for processing sensor data
US9135402B2 (en) 2007-12-17 2015-09-15 Dexcom, Inc. Systems and methods for processing sensor data
US9839395B2 (en) 2007-12-17 2017-12-12 Dexcom, Inc. Systems and methods for processing sensor data
US8473022B2 (en) 2008-01-31 2013-06-25 Abbott Diabetes Care Inc. Analyte sensor with time lag compensation
CA2715628A1 (en) 2008-02-21 2009-08-27 Dexcom, Inc. Systems and methods for processing, transmitting and displaying sensor data
CA2659142C (en) 2008-03-21 2017-10-03 Lifescan Scotland Limited Analyte testing method and system
US8396528B2 (en) 2008-03-25 2013-03-12 Dexcom, Inc. Analyte sensor
US8346335B2 (en) 2008-03-28 2013-01-01 Abbott Diabetes Care Inc. Analyte sensor calibration management
US20110028803A1 (en) * 2008-03-31 2011-02-03 Stig Ollmar Method and device for non-invasive determination of the concentration of a substance in a body fluid
US9220456B2 (en) 2008-04-04 2015-12-29 Hygieia, Inc. Systems, methods and devices for achieving glycemic balance
US8457901B2 (en) * 2008-04-04 2013-06-04 Hygieia, Inc. System for optimizing a patient's insulin dosage regimen
WO2009126900A1 (en) 2008-04-11 2009-10-15 Pelikan Technologies, Inc. Method and apparatus for analyte detecting device
WO2009139846A1 (en) * 2008-05-12 2009-11-19 Department Of Veterans Affairs Automated system and method for diabetes control
KR101148747B1 (en) * 2008-07-16 2012-05-22 파나소닉 주식회사 Battery pack
WO2010019919A1 (en) * 2008-08-14 2010-02-18 University Of Toledo Multifunctional neural network system and uses thereof for glycemic forecasting
US8734422B2 (en) 2008-08-31 2014-05-27 Abbott Diabetes Care Inc. Closed loop control with improved alarm functions
US20100057040A1 (en) 2008-08-31 2010-03-04 Abbott Diabetes Care, Inc. Robust Closed Loop Control And Methods
US8622988B2 (en) 2008-08-31 2014-01-07 Abbott Diabetes Care Inc. Variable rate closed loop control and methods
US9943644B2 (en) 2008-08-31 2018-04-17 Abbott Diabetes Care Inc. Closed loop control with reference measurement and methods thereof
US9392969B2 (en) 2008-08-31 2016-07-19 Abbott Diabetes Care Inc. Closed loop control and signal attenuation detection
US8986208B2 (en) 2008-09-30 2015-03-24 Abbott Diabetes Care Inc. Analyte sensor sensitivity attenuation mitigation
US20100174228A1 (en) * 2008-10-24 2010-07-08 Bruce Buckingham Hypoglycemia prediction and control
US8992464B2 (en) 2008-11-11 2015-03-31 Hygieia, Inc. Apparatus and system for diabetes management
US8103456B2 (en) 2009-01-29 2012-01-24 Abbott Diabetes Care Inc. Method and device for early signal attenuation detection using blood glucose measurements
US9375169B2 (en) 2009-01-30 2016-06-28 Sanofi-Aventis Deutschland Gmbh Cam drive for managing disposable penetrating member actions with a single motor and motor and control system
FR2942387A1 (en) * 2009-02-23 2010-08-27 Ecole Superieure Electricite regulation system of blood glucose of a living subject and diabetic product corresponding computer program.
US20120123234A1 (en) * 2009-02-26 2012-05-17 Eran Atlas Method and system for automatic monitoring of diabetes related treatments
WO2010111660A1 (en) 2009-03-27 2010-09-30 Dexcom, Inc. Methods and systems for promoting glucose management
US8753290B2 (en) * 2009-03-27 2014-06-17 Intellectual Inspiration, Llc Fluid transfer system and method
WO2010121084A1 (en) 2009-04-15 2010-10-21 Abbott Diabetes Care Inc. Analyte monitoring system having an alert
DE102009018649A1 (en) 2009-04-23 2010-10-28 Fresenius Medical Care Deutschland Gmbh Dialysis machine, method and apparatus for a dialysis machine
WO2010127050A1 (en) 2009-04-28 2010-11-04 Abbott Diabetes Care Inc. Error detection in critical repeating data in a wireless sensor system
EP2425209A4 (en) 2009-04-29 2013-01-09 Abbott Diabetes Care Inc Method and system for providing real time analyte sensor calibration with retrospective backfill
US20100279418A1 (en) * 2009-05-04 2010-11-04 Loren Robert Larson Glucose meter adaptable for use with handheld devices, and associated communication network
GB0909948D0 (en) * 2009-06-10 2009-07-22 Dna Electronics Ltd A glucagon pump controller
CN104799866A (en) 2009-07-23 2015-07-29 雅培糖尿病护理公司 The analyte monitoring device
EP2456351B1 (en) 2009-07-23 2016-10-12 Abbott Diabetes Care, Inc. Real time management of data relating to physiological control of glucose levels
US8478557B2 (en) 2009-07-31 2013-07-02 Abbott Diabetes Care Inc. Method and apparatus for providing analyte monitoring system calibration accuracy
EP2473422A4 (en) 2009-08-31 2014-09-17 Abbott Diabetes Care Inc Displays for a medical device
EP2473098A4 (en) * 2009-08-31 2014-04-09 Abbott Diabetes Care Inc Analyte signal processing device and methods
EP2482720A4 (en) 2009-09-29 2014-04-23 Abbott Diabetes Care Inc Method and apparatus for providing notification function in analyte monitoring systems
CA2776007A1 (en) 2009-09-30 2011-04-07 Mor Research Applications Ltd. Monitoring device for mangement of insulin delivery
US8538740B2 (en) * 2009-10-14 2013-09-17 International Business Machines Corporation Real-time performance modeling of software systems with multi-class workload
US8771251B2 (en) 2009-12-17 2014-07-08 Hospira, Inc. Systems and methods for managing and delivering patient therapy through electronic drug delivery systems
US20110184265A1 (en) * 2010-01-22 2011-07-28 Abbott Diabetes Care Inc. Method and Apparatus for Providing Notification in Analyte Monitoring Systems
US8843321B2 (en) * 2010-01-26 2014-09-23 Roche Diagnostics Operations, Inc. Methods and systems for processing glucose data measured from a person having diabetes
US9089292B2 (en) * 2010-03-26 2015-07-28 Medtronic Minimed, Inc. Calibration of glucose monitoring sensor and/or insulin delivery system
US9398869B2 (en) * 2010-03-26 2016-07-26 University Of Virginia Patent Foundation Method, system, and computer program product for improving the accuracy of glucose sensors using insulin delivery observation in diabetes
US8965476B2 (en) 2010-04-16 2015-02-24 Sanofi-Aventis Deutschland Gmbh Tissue penetration device
US9795747B2 (en) 2010-06-02 2017-10-24 Sanofi-Aventis Deutschland Gmbh Methods and apparatus for lancet actuation
US8636711B2 (en) * 2010-06-14 2014-01-28 Legacy Emanuel Hospital & Health Center Stabilized glucagon solutions and uses therefor
CN106326651A (en) * 2011-08-26 2017-01-11 弗吉尼亚大学专利基金会 Method and system for adaptive advisory control of diabetes
US8710993B2 (en) 2011-11-23 2014-04-29 Abbott Diabetes Care Inc. Mitigating single point failure of devices in an analyte monitoring system and methods thereof
US9317656B2 (en) 2011-11-23 2016-04-19 Abbott Diabetes Care Inc. Compatibility mechanisms for devices in a continuous analyte monitoring system and methods thereof
US9339217B2 (en) 2011-11-25 2016-05-17 Abbott Diabetes Care Inc. Analyte monitoring system and methods of use
US9510747B2 (en) * 2011-11-30 2016-12-06 Amo Development, Llc System and method for ophthalmic surface measurements based on objective quality estimation
WO2013082466A1 (en) * 2011-11-30 2013-06-06 Amo Development, Llc. System and method for ophthalmic surface measurements based on sequential estimates
US20130231543A1 (en) * 2012-03-05 2013-09-05 Andrea Facchinetti Method to improve safety monitoring in type-1 diabetic patients by detecting in real-time failures of the glucose
US9119529B2 (en) 2012-10-30 2015-09-01 Dexcom, Inc. Systems and methods for dynamically and intelligently monitoring a host's glycemic condition after an alert is triggered
WO2014068743A1 (en) * 2012-11-01 2014-05-08 テルモ株式会社 Sensing device and sensing method
WO2014109898A1 (en) * 2013-01-14 2014-07-17 The Regents Of University Of California Model-based personalization scheme of an artificial pancreas for type i diabetes applications
US9227014B2 (en) * 2013-02-07 2016-01-05 The Board Of Trustees Of The Laland Stanford Junior University Kalman filter based on-off switch for insulin pump
WO2014194089A1 (en) * 2013-05-29 2014-12-04 Hospira, Inc. Infusion system which utilizes one or more sensors and additional information to make an air determination regarding the infusion system
US9898585B2 (en) 2014-01-31 2018-02-20 Aseko, Inc. Method and system for insulin management
US9486580B2 (en) 2014-01-31 2016-11-08 Aseko, Inc. Insulin management
US9892234B2 (en) 2014-10-27 2018-02-13 Aseko, Inc. Subcutaneous outpatient management
US9886556B2 (en) 2015-08-20 2018-02-06 Aseko, Inc. Diabetes management therapy advisor
CN107924715A (en) * 2016-01-25 2018-04-17 普雷迪科特医疗有限公司 A plurality of non-invasive estimation substance concentration sensor

Citations (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4655225A (en) * 1985-04-18 1987-04-07 Kurabo Industries Ltd. Spectrophotometric method and apparatus for the non-invasive
US5070874A (en) * 1990-01-30 1991-12-10 Biocontrol Technology, Inc. Non-invasive determination of glucose concentration in body of patients
US5086229A (en) * 1989-01-19 1992-02-04 Futrex, Inc. Non-invasive measurement of blood glucose
US5218553A (en) * 1989-08-23 1993-06-08 The Perkin-Elmer Corporation Method for determining concentrations by means of atomic emission spectroscopy
US5298022A (en) * 1989-05-29 1994-03-29 Amplifon Spa Wearable artificial pancreas
US5308982A (en) * 1991-10-04 1994-05-03 Perkin-Elmer Corporation Method and apparatus for comparing spectra
US5494032A (en) * 1991-07-12 1996-02-27 Sandia Corporation Oximeter for reliable clinical determination of blood oxygen saturation in a fetus
US5497772A (en) * 1993-11-19 1996-03-12 Alfred E. Mann Foundation For Scientific Research Glucose monitoring system
US5685299A (en) * 1991-03-07 1997-11-11 Masimo Corporation Signal processing apparatus
US5792047A (en) * 1997-01-15 1998-08-11 Coggins; George Physiological parameter monitoring and bio-feedback apparatus
US5822715A (en) * 1997-01-10 1998-10-13 Health Hero Network Diabetes management system and method for controlling blood glucose
US5840020A (en) * 1996-02-12 1998-11-24 Nokia Mobile Phones, Ltd. Monitoring method and a monitoring equipment
US5995860A (en) * 1995-07-06 1999-11-30 Thomas Jefferson University Implantable sensor and system for measurement and control of blood constituent levels
US6023009A (en) * 1996-02-23 2000-02-08 Circe Biomedical, Inc. Artificial pancreas
US6036642A (en) * 1991-03-07 2000-03-14 Masimo Corporation Signal processing apparatus and method
US6061582A (en) * 1994-02-14 2000-05-09 University Of Iowa Research Foundation Method and apparatus for non-invasive determination of physiological chemicals, particularly glucose
US6081735A (en) * 1991-03-07 2000-06-27 Masimo Corporation Signal processing apparatus
US6083172A (en) * 1995-08-07 2000-07-04 Nellcor Puritan Bennett Incorporated Method and apparatus for estimating physiological parameters using model-based adaptive filtering
US6152876A (en) * 1997-04-18 2000-11-28 Rio Grande Medical Technologies, Inc. Method for non-invasive blood analyte measurement with improved optical interface
US6272480B1 (en) * 1997-10-17 2001-08-07 Siemens Aktiengesellschaft Method and arrangement for the neural modelling of a dynamic system with non-linear stochastic behavior
US6368272B1 (en) * 1998-04-10 2002-04-09 Proactive Metabolics Company Equipment and method for contemporaneous decision supporting metabolic control
US6413223B1 (en) * 1999-06-01 2002-07-02 Massachussetts Institute Of Technology Cuffless continuous blood pressure monitor
US6544212B2 (en) * 2001-07-31 2003-04-08 Roche Diagnostics Corporation Diabetes management system
US6558351B1 (en) * 1999-06-03 2003-05-06 Medtronic Minimed, Inc. Closed loop system for controlling insulin infusion
US6572545B2 (en) * 2000-09-22 2003-06-03 Knobbe, Lim & Buckingham Method and apparatus for real-time control of physiological parameters

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5387327A (en) * 1992-10-19 1995-02-07 Duquesne University Of The Holy Ghost Implantable non-enzymatic electrochemical glucose sensor
US5687733A (en) * 1995-10-26 1997-11-18 Baxter International Inc. System and method for estimating cardiac output
DE69725621D1 (en) 1997-03-21 2003-11-20 Nellcor Puritan Bennett Inc Method and apparatus for adaptively averaging data signals
US6216690B1 (en) * 1997-10-15 2001-04-17 Datex-Ohmeda, Inc. Method and apparatus for rapid control of set inspired gas concentration in anesthesia delivery systems
US6175752B1 (en) * 1998-04-30 2001-01-16 Therasense, Inc. Analyte monitoring device and methods of use
EP1112021A1 (en) * 1998-09-10 2001-07-04 Spectrx, Inc. Attribute compensation for analyte detection and/or continuous monitoring

Patent Citations (27)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4655225A (en) * 1985-04-18 1987-04-07 Kurabo Industries Ltd. Spectrophotometric method and apparatus for the non-invasive
US5086229A (en) * 1989-01-19 1992-02-04 Futrex, Inc. Non-invasive measurement of blood glucose
US5298022A (en) * 1989-05-29 1994-03-29 Amplifon Spa Wearable artificial pancreas
US5218553A (en) * 1989-08-23 1993-06-08 The Perkin-Elmer Corporation Method for determining concentrations by means of atomic emission spectroscopy
US5070874A (en) * 1990-01-30 1991-12-10 Biocontrol Technology, Inc. Non-invasive determination of glucose concentration in body of patients
US6036642A (en) * 1991-03-07 2000-03-14 Masimo Corporation Signal processing apparatus and method
US6263222B1 (en) * 1991-03-07 2001-07-17 Masimo Corporation Signal processing apparatus
US6236872B1 (en) * 1991-03-07 2001-05-22 Masimo Corporation Signal processing apparatus
US5685299A (en) * 1991-03-07 1997-11-11 Masimo Corporation Signal processing apparatus
US6081735A (en) * 1991-03-07 2000-06-27 Masimo Corporation Signal processing apparatus
US5494032A (en) * 1991-07-12 1996-02-27 Sandia Corporation Oximeter for reliable clinical determination of blood oxygen saturation in a fetus
US5308982A (en) * 1991-10-04 1994-05-03 Perkin-Elmer Corporation Method and apparatus for comparing spectra
US5497772A (en) * 1993-11-19 1996-03-12 Alfred E. Mann Foundation For Scientific Research Glucose monitoring system
US6061582A (en) * 1994-02-14 2000-05-09 University Of Iowa Research Foundation Method and apparatus for non-invasive determination of physiological chemicals, particularly glucose
US5995860A (en) * 1995-07-06 1999-11-30 Thomas Jefferson University Implantable sensor and system for measurement and control of blood constituent levels
US6083172A (en) * 1995-08-07 2000-07-04 Nellcor Puritan Bennett Incorporated Method and apparatus for estimating physiological parameters using model-based adaptive filtering
US5840020A (en) * 1996-02-12 1998-11-24 Nokia Mobile Phones, Ltd. Monitoring method and a monitoring equipment
US6023009A (en) * 1996-02-23 2000-02-08 Circe Biomedical, Inc. Artificial pancreas
US5822715A (en) * 1997-01-10 1998-10-13 Health Hero Network Diabetes management system and method for controlling blood glucose
US5792047A (en) * 1997-01-15 1998-08-11 Coggins; George Physiological parameter monitoring and bio-feedback apparatus
US6152876A (en) * 1997-04-18 2000-11-28 Rio Grande Medical Technologies, Inc. Method for non-invasive blood analyte measurement with improved optical interface
US6272480B1 (en) * 1997-10-17 2001-08-07 Siemens Aktiengesellschaft Method and arrangement for the neural modelling of a dynamic system with non-linear stochastic behavior
US6368272B1 (en) * 1998-04-10 2002-04-09 Proactive Metabolics Company Equipment and method for contemporaneous decision supporting metabolic control
US6413223B1 (en) * 1999-06-01 2002-07-02 Massachussetts Institute Of Technology Cuffless continuous blood pressure monitor
US6558351B1 (en) * 1999-06-03 2003-05-06 Medtronic Minimed, Inc. Closed loop system for controlling insulin infusion
US6572545B2 (en) * 2000-09-22 2003-06-03 Knobbe, Lim & Buckingham Method and apparatus for real-time control of physiological parameters
US6544212B2 (en) * 2001-07-31 2003-04-08 Roche Diagnostics Corporation Diabetes management system

Cited By (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2005081171A2 (en) * 2004-02-19 2005-09-01 Edward Henry Mathews Insulin bolus calculator for mobile communication device
WO2005081171A3 (en) * 2004-02-19 2006-09-14 Edward Henry Mathews Insulin bolus calculator for mobile communication device
WO2008057384A2 (en) * 2006-11-02 2008-05-15 The University Of North Carolina At Chapel Hill Methods and systems for determining an intravenous insulin infusion rate
WO2008057384A3 (en) * 2006-11-02 2008-09-04 Susan S Braithwaite Methods and systems for determining an intravenous insulin infusion rate
US20100137788A1 (en) * 2006-11-02 2010-06-03 Braithwaite Susan S Methods and systems for determining an intravenous insulin infusion rate to correct hyperglycemia of a patient, to maintain euglycemia of a patient, and to prevent hypoglycemia of a patient
US8721584B2 (en) * 2006-11-02 2014-05-13 The University Of North Carolina At Chapel Hill Methods and systems for determining an intravenous insulin infusion rate to correct hyperglycemia of a patient, to maintain euglycemia of a patient, and to prevent hypoglycemia of a patient
US20080214919A1 (en) * 2006-12-26 2008-09-04 Lifescan, Inc. System and method for implementation of glycemic control protocols
US20110282321A1 (en) * 2007-01-31 2011-11-17 Medtronic Minimed, Inc. Model predictive method and system for controlling and supervising insulin infusion
US20100249561A1 (en) * 2007-06-21 2010-09-30 University Of Virginia Patent Foundation LQG Artificial Pancreas Control System and Related Method
US9414782B2 (en) 2007-10-10 2016-08-16 Optiscan Biomedical Corporation Fluid component analysis systems and methods for glucose monitoring and control
US8449524B2 (en) 2007-10-10 2013-05-28 Optiscan Biomedical Corporation Fluid component analysis systems and methods for glucose monitoring and control
US9302045B2 (en) 2008-09-12 2016-04-05 Optiscan Biomedical Corporation Fluid component analysis system and method for glucose monitoring and control
US8417311B2 (en) 2008-09-12 2013-04-09 Optiscan Biomedical Corporation Fluid component analysis system and method for glucose monitoring and control
US9317657B2 (en) * 2008-11-26 2016-04-19 University Of Virginia Patent Foundation Method, system, and computer program product for tracking of blood glucose variability in diabetes
US20110264378A1 (en) * 2008-11-26 2011-10-27 University Of Virginia Patent Foundation Method, System, and Computer Program Product For Tracking of Blood Glucose Variability in Diabetes
US8577635B2 (en) * 2010-03-29 2013-11-05 Commissariat A L'energie Atomique Et Aux Energies Alternatives Calibrating method and system, recording medium for this method
US20110238350A1 (en) * 2010-03-29 2011-09-29 Commissariat A L'energie Atomique Et Aux Energies Alternatives Calibrating method and system, recording medium for this method
WO2017136218A1 (en) * 2016-02-01 2017-08-10 Dexcom, Inc. System and method for decision support using lifestyle factors

Also Published As

Publication number Publication date Type
US20020111547A1 (en) 2002-08-15 application
US20020099282A1 (en) 2002-07-25 application
WO2002024065A1 (en) 2002-03-28 application
US6572545B2 (en) 2003-06-03 grant
US6575905B2 (en) 2003-06-10 grant

Similar Documents

Publication Publication Date Title
Heise et al. Noninvasive blood glucose sensors based on near‐infrared spectroscopy
R Brown et al. A Bayesian semiparametric joint hierarchical model for longitudinal and survival data
Van Buuren et al. Multiple imputation of missing blood pressure covariates in survival analysis
US6918874B1 (en) Attribute compensation for analyte detection and/or continuous monitoring
US5355880A (en) Reliable noninvasive measurement of blood gases
US8998809B2 (en) Systems and methods for calibrating minimally invasive and non-invasive physiological sensor devices
US20050197553A1 (en) Patient management of diabetes treatment
US7392167B2 (en) Disease simulation system and method
Magni et al. Model predictive control of glucose concentration in type I diabetic patients: An in silico trial
US6045512A (en) System and method for continuous estimation and display of cardiac ejection fraction and end diastolic volume
US6678548B1 (en) Unified probabilistic framework for predicting and detecting seizure onsets in the brain and multitherapeutic device
Holstein-Rathlou et al. Renal blood flow regulation and arterial pressure fluctuations: a case study in nonlinear dynamics
US20070282186A1 (en) Blood glucose monitor with an integrated data management system
Gross et al. Performance evaluation of the MiniMed® continuous glucose monitoring system during patient home use
Hovorka et al. Closing the loop: the adicol experience
US6522912B1 (en) Ear type thermometer
Klonoff A review of continuous glucose monitoring technology
US5398688A (en) Method, system and instrument for monitoring food intake
US20120173200A1 (en) Method, System and Computer Program Product for Real-Time Detection of Sensitivity Decline in Analyte Sensors
US20090112478A1 (en) Modified Sensor Calibration Algorithm
Mastrototaro The MiniMed continuous glucose monitoring system
US6882940B2 (en) Methods and devices for prediction of hypoglycemic events
US6879971B1 (en) Automated method for building a model
US6243696B1 (en) Automated method for building a model
US20070173761A1 (en) Apparatus and method for controlling insulin infusion with state variable feedback